Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Methotrexate

Targets (1)Enzymes (8)Carriers (1)Transporters (22)Biointeractions (37)

Identification

Name

Methotrexate

Accession Number

DB00563 (APRD00353)

Type

Small Molecule

Groups

Approved

Description

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Structure

Similar Structures

Synonyms

4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Amethopterin
Methotrexat
Méthotrexate
Methotrexatum
Metotrexato
MTX
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid

External IDs

CL 14377 / CL-14377 / EMT 25299 / EMT-25299 / NSC-740 / R 9985 / R-9985

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Methotrexate Sodium	3IG1E710ZN	7413-34-5	DASQOOZCTWOQPA-GXKRWWSZSA-L

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Jamp-methotrexate	Solution	25 mg	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Jamp Pharma Corporation	2014-03-12	Not applicable
Methotrexate	Tablet	2.5 mg/1	Oral	Major	2009-06-01	2017-10-04
Methotrexate	Solution	25 mg	Intra-arterial; Intramuscular; Intravenous	Pfizer	1997-01-24	2011-05-03
Methotrexate	Tablet	2.5 mg/1	Oral	Dispensing Solutions, Inc.	1953-12-07	Not applicable
Methotrexate	Tablet	2.5 mg/1	Oral	A S Medication Solutions	1953-12-07	Not applicable
Methotrexate	Tablet	2.5 mg/1	Oral	A S Medication Solutions	1953-12-07	2017-06-20
Methotrexate	Tablet	2.5 mg/1	Oral	Rebel Distributors	1953-12-07	Not applicable
Methotrexate	Tablet	2.5 mg/1	Oral	Remedy Repack	2017-02-15	Not applicable
Methotrexate	Tablet	2.5 mg/1	Oral	DAVA Pharmaceuticals, Inc.	1953-12-07	Not applicable
Methotrexate	Injection, solution	25 mg/mL	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Hospira, Inc.	1959-08-10	2018-03-31

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-methotrexate	Tablet	2.5 mg	Oral	Pfizer	1999-09-17	Not applicable
Apo-methotrexate	Tablet	2.5 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Methotrexate	Injection, powder, lyophilized, for solution	1 g/1	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Fresenius Kabi	2000-01-22	Not applicable
Methotrexate	Injection	25 mg/mL	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Accord Healthcare Limited	2014-02-01	Not applicable
Methotrexate	Injection, solution	25 mg/mL	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Teva Parenteral Medicines, Inc.	2012-07-31	Not applicable
Methotrexate	Tablet	2.5 mg/1	Oral	Mylan Pharmaceuticals	1992-05-18	Not applicable
Methotrexate	Injection	25 mg/mL	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Mylan Institutional	2012-03-30	Not applicable
Methotrexate	Injection	25 mg/mL	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Pfizer Laboratories Div Pfizer Inc.	2012-03-30	Not applicable
Methotrexate	Injection, powder, lyophilized, for solution	1 g/1	Intra-arterial; Intramuscular; Intrathecal; Intravenous	West Ward Pharmaceutical	2005-09-06	Not applicable
Methotrexate	Injection	25 mg/mL	Intra-arterial; Intramuscular; Intrathecal; Intravenous	Pfizer Laboratories Div Pfizer Inc.	2012-03-30	Not applicable

International/Other Brands

Abitrexate (Teva) / Alltrex (Naprod) / Artrait (TRB) / Atrexel (Schering-Plough) / Bendatrexat (Bendalis) / Carditrex (Cadila) / Dermotrex (East West) / Ebetrex (Ebewe) / Emtexate / Ledertrexate (Biodim) / Maxtrex (Pfizer) / Meisusheng (Hospira) / Mexate (Cadila HC) / Rheumatrex (Wyeth KK) / Trexan (Atafarm) / Zexate (Dabur Pharma)

Categories

UNII

YL5FZ2Y5U1

CAS number

59-05-2

Weight

Average: 454.4393
Monoisotopic: 454.171315854

Chemical Formula

C₂₀H₂₂N₈O₅

InChI Key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

InChI

InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

IUPAC Name

(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid

SMILES

CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[[email protected]@H](CCC(O)=O)C(O)=O

Pharmacology

Indication

Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.

Structured Indications

Pharmacodynamics

Methotrexate is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Methotrexate inhibits folic acid reductase which is responsible for the conversion of folic acid to tetrahydrofolic acid. At two stages in the biosynthesis of purines and at one stage in the synthesis of pyrimidines, one-carbon transfer reactions occur which require specific coenzymes synthesized in the cell from tetrahydrofolic acid. Tetrahydrofolic acid itself is synthesized in the cell from folic acid with the help of an enzyme, folic acid reductase. Methotrexate looks a lot like folic acid to the enzyme, so it binds to it quite strongly and inhibits the enzyme. Thus, DNA synthesis cannot proceed because the coenzymes needed for one-carbon transfer reactions are not produced from tetrahydrofolic acid because there is no tetrahydrofolic acid. Methotrexate selectively affects the most rapidly dividing cells (neoplastic and psoriatic cells). Methotrexate is also indicated in the management of severe, active, classical, or definite rheumatoid arthritis.

Mechanism of action

Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known.

Target	Actions	Organism
ADihydrofolate reductase	inhibitor	Human

Absorption

Oral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect.

Volume of distribution

0.18 L/kg [initial volume of distribution (Vd)]
0.4 - 0.8 L/kg [steady state Vd] Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate does not cross the blood-brain-barrier.

Protein binding

50% bound to protein, primarily to albumin

Metabolism

Methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydroxylase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthetase. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. Furthermore, intestinal flora partially metabolizes methotrexate after oral administration.

Reactions:

Methotrexate
7-hydroxymethotrexate

Route of elimination

Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose.

Half life

Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.

Clearance

Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity.

Toxicity

Symptoms of overdose include bone marrow suppression and gastrointestinal toxicity. LD₅₀=43mg/kg(orally in rat).

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Methotrexate Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Canalicular multispecific organic anion transporter 1	ABCC2 IVS 23+56	(C;C) / (C;T)	T allele	ADR Directly Studied	Patients with this genotype have increased risk of toxicity with methotrexate.	Details
Methylenetetrahydrofolate reductase	---	(T;T) / (C;T)	T allele	ADR Directly Studied	Patients with this genotype have increased risk of toxicity with methotrexate.	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
Aceclofenac	The serum concentration of Methotrexate can be increased when it is combined with Aceclofenac.	Approved
Acemetacin	The serum concentration of Methotrexate can be increased when it is combined with Acemetacin.	Approved
Acetaminophen	The serum concentration of Methotrexate can be increased when it is combined with Acetaminophen.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Methotrexate.	Approved
Acetyldigoxin	Acetyldigoxin may decrease the cardiotoxic activities of Methotrexate.	Experimental
Acetylsalicylic acid	The serum concentration of Methotrexate can be increased when it is combined with Acetylsalicylic acid.	Approved, Vet Approved
Acitretin	Acitretin may increase the hepatotoxic activities of Methotrexate.	Approved
Adapalene	The serum concentration of Methotrexate can be increased when it is combined with Adapalene.	Approved
Afatinib	The serum concentration of Methotrexate can be increased when it is combined with Afatinib.	Approved
Albendazole	The serum concentration of Methotrexate can be increased when it is combined with Albendazole.	Approved, Vet Approved
Alclofenac	The serum concentration of Methotrexate can be increased when it is combined with Alclofenac.	Approved, Withdrawn
Aldosterone	The serum concentration of Methotrexate can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Methotrexate can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Methotrexate can be increased when it is combined with Alfentanil.	Approved, Illicit
Alitretinoin	Alitretinoin may increase the hepatotoxic activities of Methotrexate.	Approved, Investigational
Alminoprofen	The serum concentration of Methotrexate can be increased when it is combined with Alminoprofen.	Experimental
Aloxiprin	The serum concentration of Methotrexate can be increased when it is combined with Aloxiprin.	Experimental
Amantadine	The serum concentration of Methotrexate can be increased when it is combined with Amantadine.	Approved
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methotrexate.	Experimental
Amdinocillin	The serum concentration of Methotrexate can be increased when it is combined with Amdinocillin.	Withdrawn
Aminohippuric acid	The serum concentration of Methotrexate can be increased when it is combined with Aminohippuric acid.	Approved
Aminophylline	The serum concentration of Aminophylline can be increased when it is combined with Methotrexate.	Approved
Aminosalicylic Acid	The serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic Acid.	Approved
Amiodarone	The serum concentration of Methotrexate can be decreased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Methotrexate can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Methotrexate can be increased when it is combined with Amlodipine.	Approved
Amoxicillin	The serum concentration of Methotrexate can be increased when it is combined with Amoxicillin.	Approved, Vet Approved
Ampicillin	The serum concentration of Methotrexate can be increased when it is combined with Ampicillin.	Approved, Vet Approved
Amprenavir	The serum concentration of Methotrexate can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Methotrexate can be increased when it is combined with Amsacrine.	Approved
Andrographolide	The serum concentration of Methotrexate can be increased when it is combined with Andrographolide.	Investigational
Anisodamine	The serum concentration of Methotrexate can be increased when it is combined with Anisodamine.	Investigational
Antipyrine	The serum concentration of Methotrexate can be increased when it is combined with Antipyrine.	Approved
Apocynin	The serum concentration of Methotrexate can be increased when it is combined with Apocynin.	Investigational
Apremilast	The serum concentration of Methotrexate can be increased when it is combined with Apremilast.	Approved, Investigational
Aspoxicillin	The serum concentration of Methotrexate can be increased when it is combined with Aspoxicillin.	Experimental
Astemizole	The serum concentration of Methotrexate can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Methotrexate can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Methotrexate can be increased when it is combined with Atenolol.	Approved
Atorvastatin	The serum concentration of Methotrexate can be increased when it is combined with Atorvastatin.	Approved
Azapropazone	The serum concentration of Methotrexate can be increased when it is combined with Azapropazone.	Withdrawn
Azelastine	The serum concentration of Methotrexate can be increased when it is combined with Azelastine.	Approved
Azidocillin	The serum concentration of Methotrexate can be increased when it is combined with Azidocillin.	Approved
Azithromycin	The serum concentration of Methotrexate can be increased when it is combined with Azithromycin.	Approved
Azlocillin	The serum concentration of Methotrexate can be increased when it is combined with Azlocillin.	Approved
Bacampicillin	The serum concentration of Methotrexate can be increased when it is combined with Bacampicillin.	Approved
Balsalazide	The serum concentration of Methotrexate can be increased when it is combined with Balsalazide.	Approved, Investigational
BCG vaccine	The risk or severity of adverse effects can be increased when Methotrexate is combined with BCG vaccine.	Investigational
Bendazac	The serum concentration of Methotrexate can be increased when it is combined with Bendazac.	Experimental
Benorilate	The serum concentration of Methotrexate can be increased when it is combined with Benorilate.	Experimental
Benoxaprofen	The serum concentration of Methotrexate can be increased when it is combined with Benoxaprofen.	Withdrawn
Benzathine benzylpenicillin	The serum concentration of Methotrexate can be increased when it is combined with Benzathine benzylpenicillin.	Approved, Vet Approved
Benzocaine	The serum concentration of Methotrexate can be increased when it is combined with Benzocaine.	Approved
Benzylpenicillin	The serum concentration of Methotrexate can be increased when it is combined with Benzylpenicillin.	Approved, Vet Approved
Benzylpenicilloyl Polylysine	The serum concentration of Methotrexate can be increased when it is combined with Benzylpenicilloyl Polylysine.	Approved
Bepridil	The serum concentration of Methotrexate can be increased when it is combined with Bepridil.	Approved, Withdrawn
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Methotrexate.	Approved, Investigational
Bevonium	The serum concentration of Methotrexate can be increased when it is combined with Bevonium.	Experimental
Biperiden	The serum concentration of Methotrexate can be increased when it is combined with Biperiden.	Approved
Boceprevir	The serum concentration of Methotrexate can be increased when it is combined with Boceprevir.	Withdrawn
Bosutinib	The serum concentration of Methotrexate can be increased when it is combined with Bosutinib.	Approved
Bromfenac	The serum concentration of Methotrexate can be increased when it is combined with Bromfenac.	Approved
Bromocriptine	The serum concentration of Methotrexate can be increased when it is combined with Bromocriptine.	Approved, Investigational
Bucillamine	The serum concentration of Methotrexate can be increased when it is combined with Bucillamine.	Investigational
Bufexamac	The serum concentration of Methotrexate can be increased when it is combined with Bufexamac.	Experimental
Bumadizone	The serum concentration of Methotrexate can be increased when it is combined with Bumadizone.	Experimental
Bumetanide	The therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.	Approved
Buprenorphine	The serum concentration of Methotrexate can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Methotrexate can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methotrexate.	Approved
Caffeine	The serum concentration of Methotrexate can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Methotrexate can be increased when it is combined with Canagliflozin.	Approved
Candesartan cilexetil	The serum concentration of Methotrexate can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Methotrexate can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Methotrexate can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The serum concentration of Methotrexate can be increased when it is combined with Carbaspirin calcium.	Experimental
Carbenicillin	The serum concentration of Methotrexate can be increased when it is combined with Carbenicillin.	Approved
Carbenicillin indanyl	The serum concentration of Methotrexate can be increased when it is combined with Carbenicillin indanyl.	Approved
Carfecillin	The serum concentration of Methotrexate can be increased when it is combined with Carfecillin.	Experimental
Carprofen	The serum concentration of Methotrexate can be increased when it is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carvedilol	The serum concentration of Methotrexate can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Methotrexate can be increased when it is combined with Caspofungin.	Approved
Castanospermine	The serum concentration of Methotrexate can be increased when it is combined with Castanospermine.	Experimental
Celecoxib	The serum concentration of Methotrexate can be increased when it is combined with Celecoxib.	Approved, Investigational
Chloroquine	The serum concentration of Methotrexate can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Methotrexate can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Methotrexate can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Methotrexate can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Methotrexate can be increased when it is combined with Cholesterol.	Experimental
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cholic Acid	The serum concentration of Methotrexate can be decreased when it is combined with Cholic Acid.	Approved
Choline magnesium trisalicylate	The serum concentration of Methotrexate can be increased when it is combined with Choline magnesium trisalicylate.	Approved
Cilazapril	The serum concentration of Methotrexate can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Methotrexate can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of Methotrexate can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Methotrexate can be increased when it is combined with Clarithromycin.	Approved
Clofazimine	The serum concentration of Methotrexate can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Methotrexate can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonixin	The serum concentration of Methotrexate can be increased when it is combined with Clonixin.	Approved
Clotrimazole	The serum concentration of Methotrexate can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Cloxacillin	The serum concentration of Methotrexate can be increased when it is combined with Cloxacillin.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Methotrexate is combined with Clozapine.	Approved
Cobicistat	The serum concentration of Methotrexate can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Methotrexate can be increased when it is combined with Colchicine.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colforsin	The serum concentration of Methotrexate can be increased when it is combined with Colforsin.	Experimental
Crizotinib	The serum concentration of Methotrexate can be increased when it is combined with Crizotinib.	Approved
Curcumin	The serum concentration of Methotrexate can be increased when it is combined with Curcumin.	Investigational
Cyclacillin	The serum concentration of Methotrexate can be increased when it is combined with Cyclacillin.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Methotrexate.	Approved, Investigational
Cyclosporine	The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cymarin	Cymarin may decrease the cardiotoxic activities of Methotrexate.	Experimental
D-Limonene	The serum concentration of Methotrexate can be increased when it is combined with D-Limonene.	Investigational
Daclatasvir	The serum concentration of Methotrexate can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Methotrexate can be increased when it is combined with Dactinomycin.	Approved
Dasatinib	The serum concentration of Methotrexate can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Methotrexate can be decreased when it is combined with Daunorubicin.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Methotrexate.	Approved
dersalazine	The serum concentration of Methotrexate can be increased when it is combined with dersalazine.	Investigational
Desipramine	The serum concentration of Methotrexate can be increased when it is combined with Desipramine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Methotrexate.	Approved
Desloratadine	The serum concentration of Methotrexate can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Methotrexate can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexketoprofen	The serum concentration of Methotrexate can be increased when it is combined with Dexketoprofen.	Approved
Dexlansoprazole	The serum concentration of Methotrexate can be increased when it is combined with Dexlansoprazole.	Approved
Dexrabeprazole	The serum concentration of Methotrexate can be increased when it is combined with Dexrabeprazole.	Experimental
Dextromethorphan	The serum concentration of Methotrexate can be increased when it is combined with Dextromethorphan.	Approved
Diclofenac	The serum concentration of Methotrexate can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dicloxacillin	The serum concentration of Methotrexate can be increased when it is combined with Dicloxacillin.	Approved, Vet Approved
Difenpiramide	The serum concentration of Methotrexate can be increased when it is combined with Difenpiramide.	Experimental
Diflunisal	The serum concentration of Methotrexate can be increased when it is combined with Diflunisal.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Methotrexate.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Methotrexate.	Approved
Dihydroergotamine	The serum concentration of Methotrexate can be increased when it is combined with Dihydroergotamine.	Approved
Diltiazem	The serum concentration of Methotrexate can be increased when it is combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Methotrexate can be increased when it is combined with Dipyridamole.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.	Approved, Investigational
Doxazosin	The serum concentration of Methotrexate can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Methotrexate can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Methotrexate can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of Methotrexate can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Methotrexate can be increased when it is combined with Dronedarone.	Approved
Droxicam	The serum concentration of Methotrexate can be increased when it is combined with Droxicam.	Approved
Duvelisib	The serum concentration of Methotrexate can be increased when it is combined with Duvelisib.	Investigational
Dyphylline	The serum concentration of Dyphylline can be increased when it is combined with Methotrexate.	Approved
E-6201	The serum concentration of Methotrexate can be increased when it is combined with E-6201.	Investigational
Elbasvir	The serum concentration of Methotrexate can be increased when it is combined with Elbasvir.	Approved
Eltrombopag	The serum concentration of Methotrexate can be increased when it is combined with Eltrombopag.	Approved
Enalapril	The serum concentration of Methotrexate can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enasidenib	The serum concentration of Methotrexate can be increased when it is combined with Enasidenib.	Approved
Enzalutamide	The serum concentration of Methotrexate can be increased when it is combined with Enzalutamide.	Approved
Epicillin	The serum concentration of Methotrexate can be increased when it is combined with Epicillin.	Experimental
Epirizole	The serum concentration of Methotrexate can be increased when it is combined with Epirizole.	Approved
Ergonovine	The serum concentration of Methotrexate can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Methotrexate can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The serum concentration of Methotrexate can be decreased when it is combined with Erythromycin.	Approved, Vet Approved
Esomeprazole	The serum concentration of Methotrexate can be increased when it is combined with Esomeprazole.	Approved, Investigational
Estramustine	The serum concentration of Methotrexate can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Methotrexate can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Methotrexate can be decreased when it is combined with Estrone.	Approved
Etacrynic acid	The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.	Approved
Etanercept	The serum concentration of Methotrexate can be increased when it is combined with Etanercept.	Approved, Investigational
Ethenzamide	The serum concentration of Methotrexate can be increased when it is combined with Ethenzamide.	Experimental
Etodolac	The serum concentration of Methotrexate can be increased when it is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The serum concentration of Methotrexate can be increased when it is combined with Etofenamate.	Approved
Etoposide	The serum concentration of Methotrexate can be increased when it is combined with Etoposide.	Approved
Etoricoxib	The serum concentration of Methotrexate can be increased when it is combined with Etoricoxib.	Approved, Investigational
Etravirine	The serum concentration of Methotrexate can be increased when it is combined with Etravirine.	Approved
Evening primrose oil	The serum concentration of Methotrexate can be increased when it is combined with Evening primrose oil.	Approved
exisulind	The serum concentration of Methotrexate can be increased when it is combined with exisulind.	Investigational
Felbinac	The serum concentration of Methotrexate can be increased when it is combined with Felbinac.	Experimental
Felodipine	The serum concentration of Methotrexate can be increased when it is combined with Felodipine.	Approved, Investigational
Fenbufen	The serum concentration of Methotrexate can be increased when it is combined with Fenbufen.	Approved
Fenoprofen	The serum concentration of Methotrexate can be increased when it is combined with Fenoprofen.	Approved
Fentanyl	The serum concentration of Methotrexate can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fentiazac	The serum concentration of Methotrexate can be increased when it is combined with Fentiazac.	Experimental
Feprazone	The serum concentration of Methotrexate can be increased when it is combined with Feprazone.	Experimental
Ferulic acid	The serum concentration of Methotrexate can be increased when it is combined with Ferulic acid.	Experimental
Fexofenadine	The serum concentration of Methotrexate can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Methotrexate can be increased when it is combined with Fidaxomicin.	Approved
Fingolimod	Methotrexate may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Floctafenine	The serum concentration of Methotrexate can be increased when it is combined with Floctafenine.	Approved, Withdrawn
Flucloxacillin	The serum concentration of Methotrexate can be increased when it is combined with Flucloxacillin.	Approved
Fluconazole	The serum concentration of Methotrexate can be increased when it is combined with Fluconazole.	Approved
Flunixin	The serum concentration of Methotrexate can be increased when it is combined with Flunixin.	Vet Approved
Flunoxaprofen	The serum concentration of Methotrexate can be increased when it is combined with Flunoxaprofen.	Experimental
Fluoxetine	The serum concentration of Methotrexate can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Methotrexate can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Methotrexate can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Methotrexate can be increased when it is combined with Flurazepam.	Approved, Illicit
Flurbiprofen	The serum concentration of Methotrexate can be increased when it is combined with Flurbiprofen.	Approved, Investigational
Fluvoxamine	The serum concentration of Methotrexate can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Foscarnet	Foscarnet may increase the nephrotoxic activities of Methotrexate.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be decreased when it is combined with Methotrexate.	Approved
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.	Approved, Vet Approved
G17DT	The risk or severity of adverse effects can be increased when Methotrexate is combined with G17DT.	Investigational
Gefitinib	The serum concentration of Methotrexate can be increased when it is combined with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of Methotrexate can be increased when it is combined with Genistein.	Investigational
GI-5005	The risk or severity of adverse effects can be increased when Methotrexate is combined with GI-5005.	Investigational
Gitoformate	Gitoformate may decrease the cardiotoxic activities of Methotrexate.	Experimental
Glecaprevir	The serum concentration of Methotrexate can be increased when it is combined with Glecaprevir.	Approved
Glyburide	The serum concentration of Methotrexate can be increased when it is combined with Glyburide.	Approved
Glycerin	The serum concentration of Methotrexate can be increased when it is combined with Glycerin.	Approved, Investigational
Gramicidin D	The serum concentration of Methotrexate can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Methotrexate can be increased when it is combined with Grepafloxacin.	Withdrawn
Guacetisal	The serum concentration of Methotrexate can be increased when it is combined with Guacetisal.	Experimental
Haloperidol	The serum concentration of Methotrexate can be increased when it is combined with Haloperidol.	Approved
Hemoglobin crosfumaril	The serum concentration of Methotrexate can be increased when it is combined with Hemoglobin crosfumaril.	Experimental
Higenamine	The serum concentration of Methotrexate can be increased when it is combined with Higenamine.	Investigational
Hydrocortisone	The serum concentration of Methotrexate can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Ibuprofen	The serum concentration of Methotrexate can be increased when it is combined with Ibuprofen.	Approved
Ibuproxam	The serum concentration of Methotrexate can be increased when it is combined with Ibuproxam.	Withdrawn
Icatibant	The serum concentration of Methotrexate can be increased when it is combined with Icatibant.	Approved
Idelalisib	The serum concentration of Methotrexate can be increased when it is combined with Idelalisib.	Approved
Imatinib	The serum concentration of Methotrexate can be increased when it is combined with Imatinib.	Approved
Imidazole salicylate	The serum concentration of Methotrexate can be increased when it is combined with Imidazole salicylate.	Experimental
Imipramine	The serum concentration of Methotrexate can be increased when it is combined with Imipramine.	Approved
Indinavir	The serum concentration of Methotrexate can be decreased when it is combined with Indinavir.	Approved
Indobufen	The serum concentration of Methotrexate can be increased when it is combined with Indobufen.	Investigational
Indomethacin	The serum concentration of Methotrexate can be increased when it is combined with Indomethacin.	Approved, Investigational
Indoprofen	The serum concentration of Methotrexate can be increased when it is combined with Indoprofen.	Withdrawn
INGN 201	The risk or severity of adverse effects can be increased when Methotrexate is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Methotrexate is combined with INGN 225.	Investigational
Isavuconazonium	The serum concentration of Methotrexate can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Isoxicam	The serum concentration of Methotrexate can be increased when it is combined with Isoxicam.	Withdrawn
Itraconazole	The serum concentration of Methotrexate can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Methotrexate can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Methotrexate can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Kebuzone	The serum concentration of Methotrexate can be increased when it is combined with Kebuzone.	Experimental
Ketamine	The serum concentration of Methotrexate can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The serum concentration of Methotrexate can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The serum concentration of Methotrexate can be increased when it is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The serum concentration of Methotrexate can be increased when it is combined with Ketorolac.	Approved
Lanatoside C	Lanatoside C may decrease the cardiotoxic activities of Methotrexate.	Experimental
Lansoprazole	The serum concentration of Methotrexate can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Methotrexate can be increased when it is combined with Lapatinib.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Methotrexate is combined with Leflunomide.	Approved, Investigational
Levofloxacin	The serum concentration of Methotrexate can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levothyroxine	The serum concentration of Methotrexate can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Methotrexate can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Methotrexate can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Methotrexate can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Methotrexate can be increased when it is combined with Lisinopril.	Approved, Investigational
Lisofylline	The serum concentration of Methotrexate can be increased when it is combined with Lisofylline.	Investigational
Lomitapide	The serum concentration of Methotrexate can be increased when it is combined with Lomitapide.	Approved
Lonazolac	The serum concentration of Methotrexate can be increased when it is combined with Lonazolac.	Experimental
Loperamide	The serum concentration of Methotrexate can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Methotrexate can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Methotrexate can be increased when it is combined with Loratadine.	Approved
Lornoxicam	The serum concentration of Methotrexate can be increased when it is combined with Lornoxicam.	Approved
Losartan	The serum concentration of Methotrexate can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Methotrexate can be increased when it is combined with Lovastatin.	Approved, Investigational
Loxoprofen	The serum concentration of Methotrexate can be increased when it is combined with Loxoprofen.	Approved
Lumacaftor	The serum concentration of Methotrexate can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The serum concentration of Methotrexate can be increased when it is combined with Lumiracoxib.	Approved, Investigational
Magnesium salicylate	The serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.	Approved
Maprotiline	The serum concentration of Methotrexate can be increased when it is combined with Maprotiline.	Approved
Masoprocol	The serum concentration of Methotrexate can be increased when it is combined with Masoprocol.	Approved
Mebendazole	The serum concentration of Methotrexate can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Meclofenamic acid	The serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid.	Approved, Vet Approved
Mefenamic acid	The serum concentration of Methotrexate can be increased when it is combined with Mefenamic acid.	Approved
Mefloquine	The serum concentration of Methotrexate can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Methotrexate can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meloxicam	The serum concentration of Methotrexate can be increased when it is combined with Meloxicam.	Approved, Vet Approved
Meprobamate	The serum concentration of Methotrexate can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesalazine	The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Methotrexate is combined with Metamizole.	Withdrawn
Metampicillin	The serum concentration of Methotrexate can be increased when it is combined with Metampicillin.	Experimental
Methadone	The serum concentration of Methotrexate can be increased when it is combined with Methadone.	Approved
Meticillin	The serum concentration of Methotrexate can be increased when it is combined with Meticillin.	Approved
Metildigoxin	Metildigoxin may decrease the cardiotoxic activities of Methotrexate.	Experimental
Metoprolol	The serum concentration of Methotrexate can be increased when it is combined with Metoprolol.	Approved, Investigational
Mezlocillin	The serum concentration of Methotrexate can be increased when it is combined with Mezlocillin.	Approved
Mibefradil	The serum concentration of Methotrexate can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Methotrexate can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Methotrexate can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Methotrexate can be decreased when it is combined with Mifepristone.	Approved, Investigational
Mipomersen	Mipomersen may increase the hepatotoxic activities of Methotrexate.	Approved
Mitomycin	The serum concentration of Methotrexate can be increased when it is combined with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Methotrexate can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Mizoribine	The serum concentration of Methotrexate can be increased when it is combined with Mizoribine.	Investigational
Mofebutazone	The serum concentration of Methotrexate can be increased when it is combined with Mofebutazone.	Experimental
Morphine	The serum concentration of Methotrexate can be increased when it is combined with Morphine.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Methotrexate can be increased when it is combined with Mycophenolate mofetil.	Approved, Investigational
Mycophenolic acid	The serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.	Approved
Nabumetone	The serum concentration of Methotrexate can be increased when it is combined with Nabumetone.	Approved
Nafamostat	The serum concentration of Methotrexate can be increased when it is combined with Nafamostat.	Approved, Investigational
Nafcillin	The serum concentration of Methotrexate can be increased when it is combined with Nafcillin.	Approved
Naftifine	The serum concentration of Methotrexate can be increased when it is combined with Naftifine.	Approved
Naltrexone	The serum concentration of Methotrexate can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naproxen	The serum concentration of Methotrexate can be increased when it is combined with Naproxen.	Approved, Vet Approved
Naringenin	The serum concentration of Methotrexate can be increased when it is combined with Naringenin.	Experimental
Natalizumab	The risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.	Approved, Investigational
Nefazodone	The serum concentration of Methotrexate can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Methotrexate can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Methotrexate can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The serum concentration of Methotrexate can be increased when it is combined with Nepafenac.	Approved
Nicardipine	The serum concentration of Methotrexate can be increased when it is combined with Nicardipine.	Approved
Nifedipine	The serum concentration of Methotrexate can be decreased when it is combined with Nifedipine.	Approved
Nifenazone	The serum concentration of Methotrexate can be increased when it is combined with Nifenazone.	Experimental
Niflumic Acid	The serum concentration of Methotrexate can be increased when it is combined with Niflumic Acid.	Approved
Nilotinib	The serum concentration of Methotrexate can be increased when it is combined with Nilotinib.	Approved, Investigational
Nimesulide	The serum concentration of Methotrexate can be increased when it is combined with Nimesulide.	Approved, Withdrawn
Nisoldipine	The serum concentration of Methotrexate can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Methotrexate can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Methotrexate can be increased when it is combined with Nitrendipine.	Approved
Nitroaspirin	The serum concentration of Methotrexate can be increased when it is combined with Nitroaspirin.	Investigational
Norethisterone	The serum concentration of Methotrexate can be decreased when it is combined with Norethisterone.	Approved
Oleandrin	Oleandrin may decrease the cardiotoxic activities of Methotrexate.	Experimental
Olopatadine	The serum concentration of Methotrexate can be increased when it is combined with Olopatadine.	Approved
Olsalazine	The serum concentration of Methotrexate can be increased when it is combined with Olsalazine.	Approved
Omeprazole	The serum concentration of Methotrexate can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Orgotein	The serum concentration of Methotrexate can be increased when it is combined with Orgotein.	Vet Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Methotrexate.	Approved
Oxacillin	The serum concentration of Methotrexate can be increased when it is combined with Oxacillin.	Approved
Oxaprozin	The serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.	Approved
Oxyphenbutazone	The serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone.	Withdrawn
P-Nitrophenol	The serum concentration of Methotrexate can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methotrexate.	Approved, Vet Approved
Palmitic Acid	The serum concentration of Methotrexate can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Methotrexate can be increased when it is combined with Pantoprazole.	Approved
Parecoxib	The serum concentration of Methotrexate can be increased when it is combined with Parecoxib.	Approved
Paroxetine	The serum concentration of Methotrexate can be increased when it is combined with Paroxetine.	Approved, Investigational
Parthenolide	The serum concentration of Methotrexate can be increased when it is combined with Parthenolide.	Investigational
Penamecillin	The serum concentration of Methotrexate can be increased when it is combined with Penamecillin.	Experimental
Penimepicycline	The serum concentration of Methotrexate can be increased when it is combined with Penimepicycline.	Experimental
Perindopril	The serum concentration of Methotrexate can be increased when it is combined with Perindopril.	Approved
Peruvoside	Peruvoside may decrease the cardiotoxic activities of Methotrexate.	Experimental
Phenobarbital	The serum concentration of Methotrexate can be decreased when it is combined with Phenobarbital.	Approved
Phenoxymethylpenicillin	The serum concentration of Methotrexate can be increased when it is combined with Phenoxymethylpenicillin.	Approved, Vet Approved
Phenylbutazone	The serum concentration of Methotrexate can be increased when it is combined with Phenylbutazone.	Approved, Vet Approved
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Methotrexate.	Approved, Vet Approved
Pibrentasvir	The serum concentration of Methotrexate can be increased when it is combined with Pibrentasvir.	Approved
Pimecrolimus	The serum concentration of Methotrexate can be increased when it is combined with Pimecrolimus.	Approved, Investigational
Pimozide	The serum concentration of Methotrexate can be increased when it is combined with Pimozide.	Approved
Piperacillin	The serum concentration of Methotrexate can be increased when it is combined with Piperacillin.	Approved
Piretanide	The therapeutic efficacy of Piretanide can be decreased when used in combination with Methotrexate.	Experimental
Pirfenidone	The serum concentration of Methotrexate can be increased when it is combined with Pirfenidone.	Investigational
Piroxicam	The serum concentration of Methotrexate can be increased when it is combined with Piroxicam.	Approved, Investigational
Pirprofen	The serum concentration of Methotrexate can be increased when it is combined with Pirprofen.	Experimental
Pivampicillin	The serum concentration of Methotrexate can be increased when it is combined with Pivampicillin.	Approved
Pivmecillinam	The serum concentration of Methotrexate can be increased when it is combined with Pivmecillinam.	Approved
Platelet Activating Factor	The serum concentration of Methotrexate can be decreased when it is combined with Platelet Activating Factor.	Experimental
Ponatinib	The serum concentration of Methotrexate can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of Methotrexate can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pranoprofen	The serum concentration of Methotrexate can be increased when it is combined with Pranoprofen.	Experimental
Pravastatin	The serum concentration of Methotrexate can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Methotrexate can be increased when it is combined with Prazosin.	Approved
Prednisone	The serum concentration of Methotrexate can be increased when it is combined with Prednisone.	Approved, Vet Approved
Probenecid	The serum concentration of Methotrexate can be increased when it is combined with Probenecid.	Approved
Procaine benzylpenicillin	The serum concentration of Methotrexate can be increased when it is combined with Procaine benzylpenicillin.	Approved, Vet Approved
Progesterone	The serum concentration of Methotrexate can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Proglumetacin	The serum concentration of Methotrexate can be increased when it is combined with Proglumetacin.	Experimental
Promethazine	The serum concentration of Methotrexate can be increased when it is combined with Promethazine.	Approved
Propacetamol	The serum concentration of Methotrexate can be increased when it is combined with Propacetamol.	Approved
Propafenone	The serum concentration of Methotrexate can be increased when it is combined with Propafenone.	Approved
Propicillin	The serum concentration of Methotrexate can be increased when it is combined with Propicillin.	Experimental
Propranolol	The serum concentration of Methotrexate can be increased when it is combined with Propranolol.	Approved, Investigational
Propyphenazone	The serum concentration of Methotrexate can be increased when it is combined with Propyphenazone.	Experimental
Proquazone	The serum concentration of Methotrexate can be increased when it is combined with Proquazone.	Experimental
Proscillaridin	Proscillaridin may decrease the cardiotoxic activities of Methotrexate.	Experimental
Protriptyline	The serum concentration of Methotrexate can be increased when it is combined with Protriptyline.	Approved
PTC299	The serum concentration of Methotrexate can be increased when it is combined with PTC299.	Investigational
Quercetin	The serum concentration of Methotrexate can be increased when it is combined with Quercetin.	Experimental
Quinacrine	The serum concentration of Methotrexate can be increased when it is combined with Quinacrine.	Approved
Quinidine	The serum concentration of Methotrexate can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Methotrexate can be increased when it is combined with Quinine.	Approved
Rabeprazole	The serum concentration of Methotrexate can be increased when it is combined with Rabeprazole.	Approved, Investigational
Rabies virus inactivated antigen, A	The risk or severity of adverse effects can be increased when Methotrexate is combined with Rabies virus inactivated antigen, A.	Approved
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Methotrexate.	Approved
Ranitidine	The serum concentration of Methotrexate can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Methotrexate can be increased when it is combined with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of Methotrexate can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Methotrexate can be increased when it is combined with Regorafenib.	Approved
Reserpine	The serum concentration of Methotrexate can be decreased when it is combined with Reserpine.	Approved
Resveratrol	The serum concentration of Methotrexate can be increased when it is combined with Resveratrol.	Experimental, Investigational
Rifampicin	The serum concentration of Methotrexate can be decreased when it is combined with Rifampicin.	Approved
Rilpivirine	The serum concentration of Methotrexate can be increased when it is combined with Rilpivirine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Methotrexate is combined with Rindopepimut.	Investigational
Ritonavir	The serum concentration of Methotrexate can be decreased when it is combined with Ritonavir.	Approved, Investigational
Rofecoxib	The serum concentration of Methotrexate can be increased when it is combined with Rofecoxib.	Investigational, Withdrawn
Roflumilast	Roflumilast may increase the immunosuppressive activities of Methotrexate.	Approved
Rolapitant	The serum concentration of Methotrexate can be increased when it is combined with Rolapitant.	Approved
Salicylamide	The serum concentration of Methotrexate can be increased when it is combined with Salicylamide.	Approved
Salicylic acid	The serum concentration of Methotrexate can be increased when it is combined with Salicylic acid.	Approved, Vet Approved
Salsalate	The serum concentration of Methotrexate can be increased when it is combined with Salsalate.	Approved
Sapropterin	The serum concentration of Sapropterin can be decreased when it is combined with Methotrexate.	Approved, Investigational
Saquinavir	The serum concentration of Methotrexate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Methotrexate can be increased when it is combined with Scopolamine.	Approved
Selegiline	The serum concentration of Methotrexate can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Semapimod	The serum concentration of Methotrexate can be increased when it is combined with Semapimod.	Investigational
Seratrodast	The serum concentration of Methotrexate can be increased when it is combined with Seratrodast.	Approved
Serrapeptase	The serum concentration of Methotrexate can be increased when it is combined with Serrapeptase.	Investigational
Sertraline	The serum concentration of Methotrexate can be increased when it is combined with Sertraline.	Approved
Simeprevir	The serum concentration of Methotrexate can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Methotrexate can be increased when it is combined with Simvastatin.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methotrexate.	Approved
Sirolimus	The serum concentration of Methotrexate can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sorafenib	The serum concentration of Methotrexate can be increased when it is combined with Sorafenib.	Approved, Investigational
Spironolactone	The serum concentration of Methotrexate can be increased when it is combined with Spironolactone.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Methotrexate is combined with SRP 299.	Investigational
SRT501	The serum concentration of Methotrexate can be increased when it is combined with SRT501.	Investigational
St. John's Wort	The serum concentration of Methotrexate can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Methotrexate can be increased when it is combined with Staurosporine.	Experimental
Streptozocin	The serum concentration of Methotrexate can be decreased when it is combined with Streptozocin.	Approved
Sulbactam	The serum concentration of Methotrexate can be increased when it is combined with Sulbactam.	Approved
Sulbenicillin	The serum concentration of Methotrexate can be increased when it is combined with Sulbenicillin.	Experimental
Sulfadiazine	The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Methotrexate.	Approved, Vet Approved
Sulfamethoxazole	The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Methotrexate.	Approved
Sulfasalazine	Sulfasalazine may increase the hepatotoxic activities of Methotrexate.	Approved
Sulfinpyrazone	The serum concentration of Methotrexate can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Methotrexate.	Approved, Vet Approved
Sulindac	The serum concentration of Methotrexate can be increased when it is combined with Sulindac.	Approved
Sultamicillin	The serum concentration of Methotrexate can be increased when it is combined with Sultamicillin.	Investigational
Sumatriptan	The serum concentration of Methotrexate can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Methotrexate can be increased when it is combined with Sunitinib.	Approved, Investigational
Suprofen	The serum concentration of Methotrexate can be increased when it is combined with Suprofen.	Approved, Withdrawn
Suxibuzone	The serum concentration of Methotrexate can be increased when it is combined with Suxibuzone.	Experimental
Tacrine	The serum concentration of Methotrexate can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methotrexate.	Approved, Investigational
Talampicillin	The serum concentration of Methotrexate can be increased when it is combined with Talampicillin.	Experimental
Tamoxifen	The serum concentration of Methotrexate can be decreased when it is combined with Tamoxifen.	Approved
Tarenflurbil	The serum concentration of Methotrexate can be increased when it is combined with Tarenflurbil.	Investigational
Taurocholic Acid	The serum concentration of Methotrexate can be increased when it is combined with Taurocholic Acid.	Experimental
Tazobactam	The serum concentration of Methotrexate can be increased when it is combined with Tazobactam.	Approved
Tegafur	The risk or severity of adverse effects can be increased when Methotrexate is combined with Tegafur.	Approved
Telaprevir	The serum concentration of Methotrexate can be increased when it is combined with Telaprevir.	Withdrawn
Telmisartan	The serum concentration of Methotrexate can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Methotrexate can be increased when it is combined with Temsirolimus.	Approved
Tenidap	The serum concentration of Methotrexate can be increased when it is combined with Tenidap.	Experimental
Tenoxicam	The serum concentration of Methotrexate can be increased when it is combined with Tenoxicam.	Approved
Tepoxalin	The serum concentration of Methotrexate can be increased when it is combined with Tepoxalin.	Vet Approved
Terazosin	The serum concentration of Methotrexate can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Methotrexate can be increased when it is combined with Terfenadine.	Withdrawn
Teriflunomide	The serum concentration of Methotrexate can be increased when it is combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Methotrexate can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Methotrexate can be increased when it is combined with Testosterone.	Approved, Investigational
TG4010	The risk or severity of adverse effects can be increased when Methotrexate is combined with TG4010.	Investigational
Theophylline	The serum concentration of Theophylline can be increased when it is combined with Methotrexate.	Approved
Tiaprofenic acid	The serum concentration of Methotrexate can be increased when it is combined with Tiaprofenic acid.	Approved
Ticagrelor	The serum concentration of Methotrexate can be increased when it is combined with Ticagrelor.	Approved
Ticarcillin	The serum concentration of Methotrexate can be increased when it is combined with Ticarcillin.	Approved, Vet Approved
Tinoridine	The serum concentration of Methotrexate can be increased when it is combined with Tinoridine.	Investigational
Tofacitinib	Methotrexate may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolfenamic Acid	The serum concentration of Methotrexate can be increased when it is combined with Tolfenamic Acid.	Approved
Tolmetin	The serum concentration of Methotrexate can be increased when it is combined with Tolmetin.	Approved
Tolvaptan	The serum concentration of Methotrexate can be increased when it is combined with Tolvaptan.	Approved
Torasemide	The therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.	Approved
Tranilast	The serum concentration of Methotrexate can be increased when it is combined with Tranilast.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Methotrexate.	Approved, Investigational
Trazodone	The serum concentration of Methotrexate can be decreased when it is combined with Trazodone.	Approved, Investigational
Tribenoside	The serum concentration of Methotrexate can be increased when it is combined with Tribenoside.	Experimental
Trifluoperazine	The serum concentration of Methotrexate can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Methotrexate can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The risk or severity of adverse effects can be increased when Trimethoprim is combined with Methotrexate.	Approved, Vet Approved
Trimipramine	The serum concentration of Methotrexate can be increased when it is combined with Trimipramine.	Approved
Triptolide	The serum concentration of Methotrexate can be increased when it is combined with Triptolide.	Investigational
Troleandomycin	The serum concentration of Methotrexate can be increased when it is combined with Troleandomycin.	Approved
Valdecoxib	The serum concentration of Methotrexate can be increased when it is combined with Valdecoxib.	Investigational, Withdrawn
Velpatasvir	The serum concentration of Methotrexate can be increased when it is combined with Velpatasvir.	Approved
Venlafaxine	The serum concentration of Methotrexate can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The serum concentration of Methotrexate can be decreased when it is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Methotrexate can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Methotrexate can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Methotrexate can be increased when it is combined with Vinorelbine.	Approved, Investigational
Voxilaprevir	The serum concentration of Methotrexate can be increased when it is combined with Voxilaprevir.	Approved
Zaltoprofen	The serum concentration of Methotrexate can be increased when it is combined with Zaltoprofen.	Approved
Zileuton	The serum concentration of Methotrexate can be increased when it is combined with Zileuton.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Methotrexate can be increased when it is combined with Zimelidine.	Withdrawn
Zomepirac	The serum concentration of Methotrexate can be increased when it is combined with Zomepirac.	Withdrawn

Food Interactions

Milk appears to reduce its absorption.
Take without regard to meals. Limit caffeine intake.

References

Synthesis Reference

US2512572

General References

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81. [PubMed:15001324]
Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb;114(2):154-63. [PubMed:15639649]

External Links

Human Metabolome Database: HMDB14703
KEGG Drug: D00142
KEGG Compound: C01937
PubChem Compound: 126941
PubChem Substance: 46507678
ChemSpider: 112728
BindingDB: 66082
ChEBI: 44185
ChEMBL: CHEMBL34259
Therapeutic Targets Database: DNC000933
PharmGKB: PA450428
HET: MTX
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Methotrexate

ATC Codes

L04AX03 — Methotrexate

L01BA01 — Methotrexate

AHFS Codes

10:00.00 — Antineoplastic Agents

PDB Entries

1ao8 / 1axw / 1d1g / 1ddr / 1dds / 1df7 / 1dhi / 1dhj / 1dls / 1dra …

show 44 more

FDA label

Download (518 KB)

MSDS

Download (77 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Treatment	Malignant Neoplasm of Fourth Ventricle of Brain / Neoplasms, Brain	1
0	Completed	Device Feasibility	Juvenile Idiopathic Arthritis (JIA)	1
0	Completed	Treatment	Transplantation, Stem Cell	1
0	Recruiting	Treatment	Brain Tumor Recurrent	1
0	Withdrawn	Treatment	Brain and Central Nervous System Tumors / Malignant Lymphomas / Neurotoxicity	1
1	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Non-Hodgkin's Lymphoma (NHL)	1
1	Active Not Recruiting	Treatment	Malignant Lymphomas / Mantle Cell Lymphoma (MCL)	1
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of 7-hydroxymethotrexate / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Methotrexate	1
1	Completed	Not Available	Psoriasis	1
1	Completed	Not Available	Rheumatoid Arthritis	1
1	Completed	Basic Science	Rheumatoid Arthritis	2
1	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)	1
1	Completed	Treatment	Acute and Chronic Inflammation / Autoimmune Diseases / Disorder of Pleura and Pleural Cavity / Disorder of Synovium / Felty's Syndrome / Rheumatoid Arthritis / Rheumatoid Nodules / Sjögren's Syndrome	1
1	Completed	Treatment	Brain and Central Nervous System Tumors / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Central Nervous System Lymphoma / Intraocular Lymphoma	1
1	Completed	Treatment	Childhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma	1
1	Completed	Treatment	Congenital Hypoplastic Anemia	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)	1
1	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas	1
1	Completed	Treatment	Leukemias / Myelodysplastic Syndrome	1
1	Completed	Treatment	Lymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood	1
1	Completed	Treatment	Malignant Lymphomas	1
1	Completed	Treatment	Metastatic Breast Cancer (MBC)	1
1	Completed	Treatment	Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Plasmodium Infections	1
1	Completed	Treatment	Rheumatoid Arthritis	11
1	Completed	Treatment	Sarcomas	2
1	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder	1
1	Not Yet Recruiting	Other	Healthy Volunteers	1
1	Recruiting	Not Available	Psoriasis / Rheumatoid Arthritis	1
1	Recruiting	Other	Inflammatory Reaction	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia	1
1	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Malignancies, Hematologic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non Hodgkin Lymphoma (NHL)	1
1	Recruiting	Treatment	Agnogenic Myeloid Metaplasia / Leukemia, Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloid Leukemias / Waldenstrom's Macroglobulinemia (WM)	1
1	Recruiting	Treatment	Brain Tumor, Recurrent / Malignant Neoplasm of Fourth Ventricle of Brain / Neoplasms, Brain	1
1	Recruiting	Treatment	Castration-Resistant Prostate Carcinoma / Leukemia, Plasma Cell / Prostate Carcinoma Metastatic in the Bone / Recurrent Plasma Cell Myeloma / Stage IV Prostate Cancer	1
1	Recruiting	Treatment	Contiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia	1
1	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Sickle Cell Disorders	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Recruiting	Treatment	Lymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)	1
1	Recruiting	Treatment	Rheumatoid Arthritis	2
1	Terminated	Treatment	Acute Lymphoblastic Leukaemia Recurrent / Allergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase	1
1	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL	1
1	Terminated	Treatment	Juvenile Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Terminated	Treatment	Leukemia, Lymphoblastic, Acute / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute / Lymphoblastic Leukemia, Acute, Childhood	1
1	Terminated	Treatment	Rheumatoid Arthritis	1
1	Unknown Status	Not Available	Child Mortality	1
1	Unknown Status	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
1	Unknown Status	Treatment	Melanoma (Skin)	1
1	Withdrawn	Basic Science	Rheumatoid Arthritis	1
1, 2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
1, 2	Active Not Recruiting	Treatment	Leukemias	1
1, 2	Active Not Recruiting	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia	1
1, 2	Completed	Prevention	Malignancies, Hematologic	1
1, 2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Completed	Treatment	Active Rheumatoid Arthritis	1
1, 2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1, 2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemias	1
1, 2	Completed	Treatment	Acute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
1, 2	Completed	Treatment	Brain and Central Nervous System Tumors / Malignant Lymphomas	1
1, 2	Completed	Treatment	Cancer, Breast	1
1, 2	Completed	Treatment	Chemotherapeutic Agent Toxicity / Malignant Lymphomas / Mucositis / Neurotoxicity	1
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias / Malignant Lymphomas	1
1, 2	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions	1
1, 2	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Completed	Treatment	Leukemias	3
1, 2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
1, 2	Completed	Treatment	Malignant Lymphomas	1
1, 2	Completed	Treatment	Psoriasis	1
1, 2	Completed	Treatment	Rheumatoid Arthritis	1
1, 2	Completed	Treatment	Sclerosis, Progressive Systemic	1
1, 2	Not Yet Recruiting	Treatment	Adult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma	1
1, 2	Not Yet Recruiting	Treatment	Anemia, Refractory, With Excess of Blasts / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemias	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
1, 2	Recruiting	Treatment	Cancer, Breast	1
1, 2	Recruiting	Treatment	Central Nervous System Lymphoma	1
1, 2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1, 2	Recruiting	Treatment	Leukemias	2
1, 2	Recruiting	Treatment	Leukemias / Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) / Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)	1
1, 2	Recruiting	Treatment	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1
1, 2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia	1
1, 2	Terminated	Treatment	Anaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma	1
1, 2	Terminated	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Terminated	Treatment	Leukemias	1
1, 2	Terminated	Treatment	Non-Infectious Intermediate and Posterior Uveitis	1
1, 2	Terminated	Treatment	Relapsed T-Cell Acute Lymphoblastic Leukemia / Relapsed T-Cell Lymphoblastic Lymphoma	1
1, 2	Terminated	Treatment	Diffuse posterior uveitis / Uveitis, Intermediate	1
1, 2	Withdrawn	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
1, 2	Withdrawn	Treatment	Brain and Central Nervous System Tumors / Cancer, Breast / Cognitive/Functional Effects / Drug/Agent Toxicity by Tissue/Organ / Psychosocial Effects of Cancer and Its Treatment	1
1, 2	Withdrawn	Treatment	Malignant Lymphomas	1
2	Active Not Recruiting	Prevention	Acute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation / Hematopoietic Stem Cell Transplantation (HSCT)	1
2	Active Not Recruiting	Prevention	Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)	1
2	Active Not Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Neoplasms, Hematologic / Non-Neoplastic Hematologic and Lymphocytic Disorder	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute myeloid leukaemia (in remission) / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / RAEB-1 / RAEB-2 / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Refractory Anemia With Excess Blasts / Refractory Childhood Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Severe Combined Immunodeficiency / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)	1
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	2
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemias	1
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome RAEB 1 / Myelodysplastic Syndrome RAEB 2	1
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission	1
2	Active Not Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia	1
2	Active Not Recruiting	Treatment	Atherosclerosis / Human Immunodeficiency Virus (HIV) / Inflammatory Reaction	1
2	Active Not Recruiting	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors	1
2	Active Not Recruiting	Treatment	Chemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Malignant Lymphomas / Neurotoxicity / Radiation Toxicity	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas	1
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition	1
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Active Not Recruiting	Treatment	De Novo / Low-dose Corticosteroids Pretreatment / Secondary / Untreated Philadelphia Positive Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
2	Active Not Recruiting	Treatment	Leukaemia, Lymphoblastic / Lymphoma, Lymphoblastic	1
2	Active Not Recruiting	Treatment	Leukemias	2
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas	2
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas / Transplantation, Stem Cell	1
2	Active Not Recruiting	Treatment	Malignant Fibrous Histiocytoma (MFH) of Bone / Sarcoma, Osteogenic	1
2	Active Not Recruiting	Treatment	Malignant Lymphomas	2
2	Active Not Recruiting	Treatment	Nasal Type Extranodal NK/T-Cell Lymphoma	1
2	Active Not Recruiting	Treatment	Rheumatoid Arthritis	3
2	Completed	Not Available	Cancer, Breast	1
2	Completed	Basic Science	Rheumatoid Arthritis	1
2	Completed	Diagnostic	Adjuvant Arthritis / Rheumatoid Arthritis	1
2	Completed	Prevention	Acute Graft Versus Host Disease	1
2	Completed	Supportive Care	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Disease, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma	1
2	Completed	Supportive Care	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Intraocular Lymphoma / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Central Nervous System Hodgkin Lymphoma / Secondary Central Nervous System Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Completed	Supportive Care	Acute Lymphoblastic Leukaemias (ALL)	1
2	Completed	Supportive Care	Cancers	1
2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Hematopoietic/Lymphoid Cancer / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia	1
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	3
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemias	1
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
2	Completed	Treatment	Acute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL)	1
2	Completed	Treatment	Adult Acute Lymphoblastic Leukemia in Remission	1
2	Completed	Treatment	Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)	1
2	Completed	Treatment	Adult-Onset Still's Disease	1
2	Completed	Treatment	All / Aplastic Anaemia (AA) / CLL / CML Chronic Phase, Accelerated Phase, or Blast Crisis / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) / RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA / Smith-Magenis Syndrome	1
2	Completed	Treatment	Aplastic Anaemia (AA)	2
2	Completed	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Bladder Cancers	3
2	Completed	Treatment	Bladder Cancers / Muscle-invasive Bladder Cancer	1
2	Completed	Treatment	Brain and Central Nervous System Tumors	3
2	Completed	Treatment	Burkitt's Lymphoma / Burkitt'S-like Lymphoma	1
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Cancer, Breast / Cancer, Ovarian	1
2	Completed	Treatment	Cancer, Breast / Neoplasms, Breast	1
2	Completed	Treatment	Cancer, Ovarian / Extragonadal Germ Cell Tumor	1
2	Completed	Treatment	Cancers / Leukemias / Malignant Lymphomas	1
2	Completed	Treatment	Central Nervous System Lymphoma	2
2	Completed	Treatment	Central Nervous System Metastases / Leptomeningeal Metastases / Recurrent Breast Cancer / Stage IV Breast Cancer / Tumors Metastatic to Brain	1
2	Completed	Treatment	Central Nervous System Tumor, Pediatric	1
2	Completed	Treatment	Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Chronic Myelogenous Leukemia (CML) / Leukemias	1
2	Completed	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia	1
2	Completed	Treatment	Desmoid Tumors	1
2	Completed	Treatment	Estrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer	1
2	Completed	Treatment	Estrogen Receptor-negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer	1
2	Completed	Treatment	Giant Cells Arteritis	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Malignancies, Hematologic	2
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Malignant Lymphomas	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Transplantation, Bone Marrow	1
2	Completed	Treatment	Granulomatosis With Polyangiitis / Inflammatory Reaction / Vasculitis	1
2	Completed	Treatment	Head and Neck Carcinoma	1
2	Completed	Treatment	High Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer	1
2	Completed	Treatment	Hodgkins Disease (HD)	2
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2	Completed	Treatment	Intraluminal Pulmonary Vein Stenosis	1
2	Completed	Treatment	Langerhans Cell Histiocytosis (LCH)	1
2	Completed	Treatment	Leptomeningeal Metastasis / Metastatic Brain Tumors / Neoplasms, Breast	1
2	Completed	Treatment	Leukemia, Lymphocytic, Acute	1
2	Completed	Treatment	Leukemias	23
2	Completed	Treatment	Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas	7
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Plasma Cell Neoplasms	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myeloproliferative Disorders / Renal Cancers	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes	1
2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes	4
2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	2
2	Completed	Treatment	Leukemias / Neutropenias / Thrombocytopenias	1
2	Completed	Treatment	Lymphohistiocytosis, Hemophagocytic	1
2	Completed	Treatment	Lymphoma, B Cell	1
2	Completed	Treatment	Malignant Lymphomas	21
2	Completed	Treatment	Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm	2
2	Completed	Treatment	Metastatic Osteosarcoma	1
2	Completed	Treatment	Multiple Myeloma (MM)	1
2	Completed	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
2	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
2	Completed	Treatment	Myasthenia Gravis	1
2	Completed	Treatment	Neuroendocrine Carcinoma of the Skin	1
2	Completed	Treatment	Neurofibromatosis Type 1 / Precancerous Conditions	1
2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	2
2	Completed	Treatment	Psoriatic Arthritis	1
2	Completed	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Renal Cancers	1
2	Completed	Treatment	Rheumatoid Arthritis	24
2	Completed	Treatment	Rheumatoid Arthritis / Synovitis	1
2	Completed	Treatment	Sarcoma, Osteogenic	1
2	Completed	Treatment	Sarcomas	1
2	Completed	Treatment	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1
2	Completed	Treatment	Ulcerative Colitis (UC)	2
2	Completed	Treatment	Untreated Childhood Medulloblastoma	1
2	Completed	Treatment	Uveitis	1
2	Enrolling by Invitation	Treatment	Acute,Leukemia, Lymphoid	1
2	Enrolling by Invitation	Treatment	Graft Versus Host Disease (GVHD)	1
2	Not Yet Recruiting	Prevention	Graft Versus Host Disease (GVHD)	1
2	Not Yet Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2	Not Yet Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)	1
2	Not Yet Recruiting	Treatment	Autoimmune Diseases	1
2	Not Yet Recruiting	Treatment	Labor; Forced or Induced, Affecting Fetus or Newborn	1
2	Not Yet Recruiting	Treatment	Rheumatoid Arthritis	1
2	Recruiting	Other	Coronary Artery Disease	1
2	Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)	1
2	Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-1 / RAEB-2 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts	1
2	Recruiting	Treatment	Acute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Philadelphia Chromosome Positive / Recurrent Adult Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Children	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemias	1
2	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	All	1
2	Recruiting	Treatment	Atypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)	1
2	Recruiting	Treatment	B-cell Acute Lymphoblastic Leukemia	1
2	Recruiting	Treatment	Bladder Cancers	1
2	Recruiting	Treatment	Chronic Myelogenous Leukemia (CML) / Chronic Myelomonocytic Leukemia (CMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)	1
2	Recruiting	Treatment	Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Colorectal Cancers	1
2	Recruiting	Treatment	Epstein Barr Virus Associated Hodgkin's Lymphoma / Epstein Barr Virus Associated Non Hodgkin's Lymphoma / Post-transplant Lymphoproliferative Disease (PTLD)	1
2	Recruiting	Treatment	High Grade Osteosarcoma	1
2	Recruiting	Treatment	Langerhans Cell Histiocytosis (LCH)	1
2	Recruiting	Treatment	Large B-cell Diffuse Lymphoma of Testis / Primary Testicular Diffuse Large B-cell Lymphoma	1
2	Recruiting	Treatment	Large Granular Lymphocytes Leukemia	1
2	Recruiting	Treatment	Leptomeningeal Metastasis	1
2	Recruiting	Treatment	Leukaemia, Lymphoblastic	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes	2
2	Recruiting	Treatment	Leukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic	1
2	Recruiting	Treatment	Leukemias	6
2	Recruiting	Treatment	Localized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	1
2	Recruiting	Treatment	Lymphoma, AIDS Related / Neoplasms, Brain	1
2	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
2	Recruiting	Treatment	Lymphoma, Mantle-Cell / Malignant Lymphomas	1
2	Recruiting	Treatment	Malignant Lymphomas	1
2	Recruiting	Treatment	Malignant Pleural Mesothelioma (MPM) / Mesothelioma	1
2	Recruiting	Treatment	Metastatic Breast Cancer (MBC)	1
2	Recruiting	Treatment	Non-Malignant	1
2	Recruiting	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	2
2	Recruiting	Treatment	Primary Myelofibrosis / Secondary Myelofibrosis	1
2	Recruiting	Treatment	Progressive Desmoids Tumors	1
2	Recruiting	Treatment	Psoriasis Vulgaris	1
2	Recruiting	Treatment	Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	Rheumatoid Arthritis	7
2	Recruiting	Treatment	Sarcoma, Osteogenic	1
2	Recruiting	Treatment	Sickle Cell Disorders	1
2	Recruiting	Treatment	Stage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma	1
2	Recruiting	Treatment	Tumors, Solid	1
2	Recruiting	Treatment	Urothelial Carcinoma of the Bladder	1
2	Suspended	Treatment	Anaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma	1
2	Suspended	Treatment	Malignant Lymphomas	1
2	Suspended	Treatment	Unrecognized Condition: Mature B or T-cell Neoplasm	1
2	Terminated	Prevention	Graft Versus Host Disease (GVHD)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
2	Terminated	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia	1
2	Terminated	Treatment	Advanced Colorectal Cancer	1
2	Terminated	Treatment	Aplastic Anaemia (AA)	1
2	Terminated	Treatment	Atypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	B-cell Childhood Acute Lymphoblastic Leukemia / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / L3 Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma	1
2	Terminated	Treatment	Bladder Cancers	3
2	Terminated	Treatment	Breast Cancer, Metastatic / Cancer treatment	1
2	Terminated	Treatment	Cancer, Breast	2
2	Terminated	Treatment	Cardiac Toxicity / Sarcomas	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood	1
2	Terminated	Treatment	Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer	1
2	Terminated	Treatment	Extranodal NK/T-cell Lymphoma, Nasal Type	1
2	Terminated	Treatment	Follicular Lymphoma (FL)	1
2	Terminated	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)	1
2	Terminated	Treatment	Leukemia, Lymphoblastic, Acute / Leukemia, Myelogenous, Acute / Minimal Residual Disease	1
2	Terminated	Treatment	Leukemias	3
2	Terminated	Treatment	Leukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas / Myeloproliferative Disorders / Plasma Cell Myeloma	1
2	Terminated	Treatment	Lymphoma, Lymphoblastic	1
2	Terminated	Treatment	Malignant Lymphomas	4
2	Terminated	Treatment	Metastatic Colorectal Cancers	1
2	Terminated	Treatment	Ovarian Carcinoma	1
2	Terminated	Treatment	Recurrent Adult Acute Lymphoblastic Leukemia	1
2	Terminated	Treatment	Rheumatoid Arthritis	11
2	Terminated	Treatment	Sarcoma, Osteogenic / Spindle Cell Sarcoma of Bone	1
2	Terminated	Treatment	Urticarias	1
2	Unknown Status	Educational/Counseling/Training	Ankylosing Spondylitis (AS)	1
2	Unknown Status	Prevention	Graft Versus Host Disease (GVHD)	1
2	Unknown Status	Supportive Care	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Brain and Central Nervous System Tumors	1
2	Unknown Status	Treatment	Brain and Central Nervous System Tumors / Lymphoproliferative Disorders / Malignant Lymphomas / Small Intestine Cancer	1
2	Unknown Status	Treatment	Brain and Central Nervous System Tumors / Neuroblastomas	1
2	Unknown Status	Treatment	Cancer, Breast	6
2	Unknown Status	Treatment	Cancer, Ovarian	1
2	Unknown Status	Treatment	Central Serous Chorioretinopathy (CSC)	1
2	Unknown Status	Treatment	Churg-Strauss Syndrome (CSS) / Granulomatosis With Polyangiitis / Microscopic Polyangiitis / Polyarteritis Nodosa	1
2	Unknown Status	Treatment	Fingernail Psoriasis	1
2	Unknown Status	Treatment	Improvement in Function / Reduction in Pain / Reduction of Inflammation	1
2	Unknown Status	Treatment	Leukemias	3
2	Unknown Status	Treatment	Leukemias / Malignant Lymphomas	1
2	Unknown Status	Treatment	Lymphoblastic Leukemia, Acute	1
2	Unknown Status	Treatment	Lymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia	1
2	Unknown Status	Treatment	Malignant Lymphomas	5
2	Unknown Status	Treatment	Malignant Lymphomas / Small Intestine Cancer	1
2	Unknown Status	Treatment	Mesothelioma, Malignant	1
2	Unknown Status	Treatment	Myocardial Infarction (MI)	1
2	Unknown Status	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Unknown Status	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	1
2	Unknown Status	Treatment	Primary Non Hodgkin Lymphoma of the Central Nervous System	2
2	Unknown Status	Treatment	Refractory Follicular Lymphoma	1
2	Unknown Status	Treatment	Renal Cancers	1
2	Withdrawn	Prevention	Aging / Inflammatory Reaction	1
2	Withdrawn	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias	1
2	Withdrawn	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2	Withdrawn	Treatment	Anemias / Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Withdrawn	Treatment	Anterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer	1
2	Withdrawn	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Withdrawn	Treatment	Brain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas	1
2	Withdrawn	Treatment	Recurrent Breast Cancer / Stage IV Breast Cancer	1
2	Withdrawn	Treatment	Systemic Lupus Erythematosus (SLE)	1
2, 3	Active Not Recruiting	Treatment	Childhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma	1
2, 3	Completed	Prevention	Graft Versus Host Disease (GVHD)	1
2, 3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2, 3	Completed	Treatment	Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2, 3	Completed	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer	1
2, 3	Completed	Treatment	Heart Failure, Unspecified / Myocardial Ischemia	1
2, 3	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes	1
2, 3	Completed	Treatment	Rheumatoid Arthritis	2
2, 3	Not Yet Recruiting	Treatment	Juanbi Pill / Rheumatoid Arthritis	1
2, 3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma	1
2, 3	Recruiting	Treatment	Childhood Ependymoma	1
2, 3	Recruiting	Treatment	Langerhans Cell Histiocytosis (LCH)	1
2, 3	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
2, 3	Recruiting	Treatment	Leukemias	1
2, 3	Recruiting	Treatment	Lymphoma, Lymphoblastic	1
2, 3	Recruiting	Treatment	Mature B-Cell Lymphoma	1
2, 3	Recruiting	Treatment	Mature B-cell Non-Hodgkin Lymphoma	1
2, 3	Recruiting	Treatment	Psoriasis	1
2, 3	Recruiting	Treatment	Sarcoma, Osteogenic	1
2, 3	Terminated	Treatment	Dermatomyositis	1
2, 3	Terminated	Treatment	Follicular Lymphoma (FL) / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma	1
2, 3	Unknown Status	Treatment	Leukemias	1
2, 3	Unknown Status	Treatment	Mucopolysaccharidosis	1
2, 3	Unknown Status	Treatment	Osteopetrosis	1
2, 3	Unknown Status	Treatment	Rheumatoid Arthritis	1
3	Active Not Recruiting	Not Available	Brain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Ototoxicity	1
3	Active Not Recruiting	Not Available	Cancer, Breast	1
3	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
3	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	Acute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	B-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	B-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	B-cell Non Hodgkin's Lymphoma / Mature B-cell Leukemia Burkitt-type	1
3	Active Not Recruiting	Treatment	Cancer, Breast	1
3	Active Not Recruiting	Treatment	Childhood Acute Promyelocytic Leukemia (M3) / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
3	Active Not Recruiting	Treatment	Childhood Atypical Teratoid/Rhabdoid Tumor	1
3	Active Not Recruiting	Treatment	Choriocarcinoma / FIGO Stage I Gestational Trophoblastic Tumor / FIGO Stage II Gestational Trophoblastic Tumor / FIGO Stage III Gestational Trophoblastic Tumor / Hydatidiform Mole	1
3	Active Not Recruiting	Treatment	Disorder Related to Bone Marrow Transplantation / Leukemias / Transplantation Infection	1
3	Active Not Recruiting	Treatment	Drug/Agent Toxicity by Tissue/Organ / Leukemias	1
3	Active Not Recruiting	Treatment	Head and Neck Squamous Cell Cancer	1
3	Active Not Recruiting	Treatment	Leukemias	3
3	Active Not Recruiting	Treatment	Localized Osteosarcoma / Metastatic Osteosarcoma	1
3	Active Not Recruiting	Treatment	Lymphoblastic Leukemia, Acute	1
3	Active Not Recruiting	Treatment	Malignant Lymphomas	1
3	Active Not Recruiting	Treatment	Neoplasms, Head and Neck / Squamous Cell Carcinoma (SCC)	1
3	Active Not Recruiting	Treatment	Plaque Psoriasis	1
3	Active Not Recruiting	Treatment	Psoriatic Arthritis	1
3	Active Not Recruiting	Treatment	Recurrent or Metastatic Head and Neck Carcinoma	1
3	Active Not Recruiting	Treatment	Rheumatoid Arthritis	6
3	Active Not Recruiting	Treatment	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1
3	Completed	Not Available	Psoriasis Vulgaris	1
3	Completed	Other	Rheumatoid Arthritis	1
3	Completed	Prevention	Graft Versus Host Disease (GVHD) / Survival	1
3	Completed	Prevention	Rheumatoid Arthritis	1
3	Completed	Supportive Care	Cancer, Breast	1
3	Completed	Supportive Care	Cardiac Toxicity / Leukemias / Malignant Lymphomas	1
3	Completed	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
3	Completed	Treatment	Active Rheumatoid Arthritis	2
3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	2
3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Hodgkins Disease (HD) / Myelodysplastic Syndrome	1
3	Completed	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes	1
3	Completed	Treatment	Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Promyelocytic Leukemia (M3) / Childhood Acute Promyelocytic Leukemia (M3) / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
3	Completed	Treatment	Ankylosing Spondylitis (AS)	1
3	Completed	Treatment	Arthritis / Autoimmune Diseases / Rheumatoid Arthritis	1
3	Completed	Treatment	Atopic Dermatitis (AD)	1
3	Completed	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer	1
3	Completed	Treatment	Bladder Cancers / Urethral Cancer	1
3	Completed	Treatment	Cancer, Breast	17
3	Completed	Treatment	Cardiac Toxicity / Sarcomas	1
3	Completed	Treatment	Cervical Cancers	1
3	Completed	Treatment	Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
3	Completed	Treatment	Childhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia	1
3	Completed	Treatment	Crohn's Disease (CD)	1
3	Completed	Treatment	Dermatomyositis / Polymyositis	1
3	Completed	Treatment	Disseminated Sclerosis / Macular Edema (ME) / Uveitis, Intermediate	1
3	Completed	Treatment	Early Rheumatoid Arthritis	2
3	Completed	Treatment	Early Stage Breast Cancer	1
3	Completed	Treatment	Early-Stage Breast Cancer	1
3	Completed	Treatment	Extrauterine Pregnancy	1
3	Completed	Treatment	Good Prognosis Metastatic Gestational Trophoblastic Tumor / Hydatidiform Mole / Non-Metastatic Gestational Trophoblastic Tumor / Uterine Corpus Choriocarcinoma	1
3	Completed	Treatment	Head and Neck Carcinoma	2
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)	1
3	Completed	Treatment	Hydatidiform Mole	1
3	Completed	Treatment	Juvenile Idiopathic Arthritis (JIA)	1
3	Completed	Treatment	Leukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Myelodysplastic Syndromes	1
3	Completed	Treatment	Leukemia, Myelocytic, Acute	2
3	Completed	Treatment	Leukemias	16
3	Completed	Treatment	Leukemias / Malignant Lymphomas	4
3	Completed	Treatment	Leukemias / Myelodysplastic Syndromes	2
3	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
3	Completed	Treatment	Liver Cirrhosis, Biliary	3
3	Completed	Treatment	Localised High Grade Osteosarcoma of the Limbs / Sarcoma, Osteogenic	1
3	Completed	Treatment	Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)	1
3	Completed	Treatment	Malignant Lymphomas	5
3	Completed	Treatment	Neoplasms, Breast	1
3	Completed	Treatment	Plaque Psoriasis	1
3	Completed	Treatment	Psoriasis	5
3	Completed	Treatment	Psoriatic Arthritis	1
3	Completed	Treatment	Rheumatoid Arthritis	60
3	Completed	Treatment	Sarcoma, Osteogenic	1
3	Completed	Treatment	Seronegative Spondyloarthropathies	1
3	Completed	Treatment	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1
3	Completed	Treatment	Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder	1
3	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
3	Completed	Treatment	Untreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor	1
3	Completed	Treatment	Uveitis	1
3	Not Yet Recruiting	Treatment	Gestational Trophoblastic Neoplasms	1
3	Not Yet Recruiting	Treatment	Low Dose Methotrexate in Severe Chronic Asthma	1
3	Not Yet Recruiting	Treatment	Rheumatoid Arthritis	1
3	Recruiting	Prevention	Acute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
3	Recruiting	Prevention	Leukaemia, Acute / Myelodysplasia	1
3	Recruiting	Prevention	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
3	Recruiting	Supportive Care	Acute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukemia, Pediatric	1
3	Recruiting	Treatment	Acute Promyelocytic Leukemia (APL)	1
3	Recruiting	Treatment	Adult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Alopecia Areata (AA)	1
3	Recruiting	Treatment	Atherosclerotic Cardiovascular Diseases / Vascular Inflammation	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Cardiovascular Disease (CVD)	1
3	Recruiting	Treatment	Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type	1
3	Recruiting	Treatment	Extranodal NK/T-cell Lymphoma, Nasal Type	1
3	Recruiting	Treatment	Extrauterine Pregnancy / Persistent Pregnancy of Unknown Location	1
3	Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
3	Recruiting	Treatment	Head Neck Cancer Squamous Cell Recurrent	1
3	Recruiting	Treatment	Juvenile Idiopathic Arthritis (JIA)	1
3	Recruiting	Treatment	Mature B-cell Non-Hodgkin Lymphoma	1
3	Recruiting	Treatment	Moderate and Severe RheumatoId Arthritis	1
3	Recruiting	Treatment	Neoplasms, Head and Neck	1
3	Recruiting	Treatment	Pediatric Crohn's Disease	1
3	Recruiting	Treatment	Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	1
3	Recruiting	Treatment	Psoriatic Arthritis	3
3	Recruiting	Treatment	Rheumatoid Arthritis	8
3	Recruiting	Treatment	Takayasu's Disease	1
3	Recruiting	Treatment	Uveitis	1
3	Suspended	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Suspended	Treatment	Brain Cancer / Choroid Plexus Tumors	1
3	Suspended	Treatment	Cancer, Breast	1
3	Terminated	Prevention	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Myeloproliferative Disorders	1
3	Terminated	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
3	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
3	Terminated	Treatment	Cancer, Breast	1
3	Terminated	Treatment	Hearing Loss, Sensorineural	1
3	Terminated	Treatment	Juvenile Idiopathic Arthritis (JIA)	1
3	Terminated	Treatment	Leukemias	1
3	Terminated	Treatment	Malignant Lymphomas	1
3	Terminated	Treatment	Psoriasis	1
3	Terminated	Treatment	Rheumatoid Arthritis	4
3	Terminated	Treatment	Sarcomas	1
3	Unknown Status	Treatment	Bladder Cancers	1
3	Unknown Status	Treatment	Brain and Central Nervous System Tumors	2
3	Unknown Status	Treatment	Cancer, Breast	2
3	Unknown Status	Treatment	Chronic Periaortitis / Idiopathic Retroperitoneal Fibrosis / Perianeurysmal Retroperitoneal Fibrosis	1
3	Unknown Status	Treatment	Chronic Urticaria	1
3	Unknown Status	Treatment	Juvenile Dermatomyositis	1
3	Unknown Status	Treatment	Leukemias	3
3	Unknown Status	Treatment	Leukemias / Malignant Lymphomas	1
3	Unknown Status	Treatment	Leukemias / Mucositis / Oral Complications	1
3	Unknown Status	Treatment	Lymphoblastic Leukemia, Acute	1
3	Unknown Status	Treatment	Malignant Lymphomas	4
3	Unknown Status	Treatment	Nonneoplastic Condition	1
3	Unknown Status	Treatment	Polyarthritis	1
3	Unknown Status	Treatment	Rheumatoid Arthritis	2
3	Withdrawn	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
3	Withdrawn	Treatment	Leukemias	1
4	Active Not Recruiting	Basic Science	Psoriasis	1
4	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
4	Active Not Recruiting	Treatment	Rheumatoid Arthritis	3
4	Completed	Not Available	Psoriatic Arthritis	1
4	Completed	Not Available	Relapsing Remitting Multiple Sclerosis (RRMS)	1
4	Completed	Not Available	Rheumatoid Arthritis	1
4	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	4
4	Completed	Treatment	Adult Acute Lymphocytic Leukemia	4
4	Completed	Treatment	Ankylosing Spondylitis (AS)	2
4	Completed	Treatment	Arthritis, Juvenile Rheumatoid / Juvenile Chronic Polyarthritis / Juvenile Idiopathic Arthritis (JIA)	1
4	Completed	Treatment	Burkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms	1
4	Completed	Treatment	Central Nervous System Lymphoma	1
4	Completed	Treatment	Crohn's Disease (CD)	1
4	Completed	Treatment	Disseminated Sclerosis	1
4	Completed	Treatment	Extrauterine Pregnancy	2
4	Completed	Treatment	Glycogen Storage Disease Type II / Pompe's Disease	1
4	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
4	Completed	Treatment	Lymphoma, Lymphoblastic	1
4	Completed	Treatment	Psoriasis	4
4	Completed	Treatment	Psoriasis / Psoriatic Arthritis	1
4	Completed	Treatment	Rheumatoid Arthritis	30
4	Completed	Treatment	Unwanted Pregnancies	1
4	Completed	Treatment	Uveitis	1
4	Enrolling by Invitation	Basic Science	Rheumatoid Arthritis	1
4	Enrolling by Invitation	Treatment	Childhood Acute Promyelocytic Leukemia	1
4	Enrolling by Invitation	Treatment	Ulcerative Colitis (UC)	1
4	Not Yet Recruiting	Treatment	Cardiovascular Risk Factors / Endothelial Dysfunction / Rheumatoid Arthritis / Stiffness, Aortic	1
4	Not Yet Recruiting	Treatment	Crohn's Disease (CD)	1
4	Not Yet Recruiting	Treatment	Insufficient Response to Methotrexate / Rheumatoid Arthritis	1
4	Not Yet Recruiting	Treatment	Juvenile Idiopathic Arthritis (JIA)	1
4	Not Yet Recruiting	Treatment	Nonleukemic meningeal cancer	1
4	Not Yet Recruiting	Treatment	Ph+ Acute Lymphoblastic Leukemia	1
4	Recruiting	Basic Science	Rheumatoid Arthritis	1
4	Recruiting	Prevention	Acute Graft Versus Host Disease	1
4	Recruiting	Prevention	Beta-Thalassemia Major	1
4	Recruiting	Treatment	ALK-negative Anaplastic Large Cell Lymphoma / Angioimmunoblastic T Cell Lymphoma / Enteropathy Associated T Cell Lymphoma / Hepatosplenic T Cell Lymphoma / Peripherial T Cell Lymphoma,Not Otherwise Specified / Subcutaneous Panniculitis Like T Cell Lymphoma	1
4	Recruiting	Treatment	APL	1
4	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	4
4	Recruiting	Treatment	Crohn's Disease (CD)	3
4	Recruiting	Treatment	Glycogen Storage Disease Type II (GSD-II) / Glycogenesis 2 Acid Maltase Deficiency / Pompe's Disease	1
4	Recruiting	Treatment	Lymphoma, T-Cell, Cutaneous / Mycosis Fungoides (MF)	1
4	Recruiting	Treatment	Ophthalmopathy, Thyroid-Associated	1
4	Recruiting	Treatment	Pompe's Disease	1
4	Recruiting	Treatment	Psoriasis	1
4	Recruiting	Treatment	Psoriatic Arthritis	1
4	Recruiting	Treatment	Rheumatoid Arthritis	7
4	Recruiting	Treatment	Thalassemia Major (TM)	1
4	Terminated	Treatment	Macular Edema (ME) / Ocular Sarcoidosis / Sarcoid-associated Uveitis	1
4	Terminated	Treatment	Moderate to Severe Rheumatoid Arthritis	1
4	Terminated	Treatment	Rheumatoid Arthritis	5
4	Unknown Status	Prevention	Rheumatoid Arthritis	1
4	Unknown Status	Treatment	Adult Acute Lymphocytic Leukemia	2
4	Unknown Status	Treatment	Arthritis / Rheumatoid Arthritis	2
4	Unknown Status	Treatment	Extrauterine Pregnancy	1
4	Unknown Status	Treatment	Rheumatoid Arthritis	2
4	Unknown Status	Treatment	Severe Plaque Type Psoriasis	1
4	Withdrawn	Treatment	Ankylosing Spondylitis (AS) / Spondylarthropathy	1
4	Withdrawn	Treatment	Demyelinating Disorders / Disseminated Sclerosis / Myelitis NOS / Neuritis / Optic Neuritis	1
4	Withdrawn	Treatment	Rheumatoid Arthritis	2
Not Available	Active Not Recruiting	Not Available	JIA / Juvenile Idiopathic Arthritis (JIA)	1
Not Available	Active Not Recruiting	Not Available	Rheumatoid Arthritis	1
Not Available	Active Not Recruiting	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
Not Available	Active Not Recruiting	Treatment	Early Chikungunya Arthritis	1
Not Available	Active Not Recruiting	Treatment	Leukemias	1
Not Available	Active Not Recruiting	Treatment	Malignant Lymphomas	1
Not Available	Completed	Not Available	Ankylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis	1
Not Available	Completed	Not Available	Arthritis / High Dose / Rheumatoid	1
Not Available	Completed	Not Available	Dermatomyositis / Polymyositis	1
Not Available	Completed	Not Available	Early Diffuse Cutaneous Systemic Sclerosis	1
Not Available	Completed	Not Available	Inflammatory Bowel Diseases (IBD) / Psoriasis	1
Not Available	Completed	Not Available	Inflammatory Reaction / Psoriasis	1
Not Available	Completed	Not Available	Leukemias / Nephrotoxicity	1
Not Available	Completed	Not Available	Methotrexate Adverse Reaction	1
Not Available	Completed	Not Available	Psoriasis	1
Not Available	Completed	Not Available	Rheumatoid Arthritis	2
Not Available	Completed	Not Available	Sarcoma, Osteogenic	1
Not Available	Completed	Not Available	Sarcoma, Osteogenic / Spindle Cell Sarcoma of Bone	1
Not Available	Completed	Basic Science	Rheumatoid Arthritis	1
Not Available	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
Not Available	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)	1
Not Available	Completed	Treatment	Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome With Isolated Del(5q) / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
Not Available	Completed	Treatment	Ataxia-Telangiectasia	1
Not Available	Completed	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
Not Available	Completed	Treatment	Brain and Central Nervous System Tumors	2
Not Available	Completed	Treatment	Brain and Central Nervous System Tumors / Malignant Lymphomas	1
Not Available	Completed	Treatment	Cancer, Breast	2
Not Available	Completed	Treatment	Childhood Acute Lymphoblastic Leukemia in Remission	1
Not Available	Completed	Treatment	Childhood Langerhans Cell Histiocytosis	1
Not Available	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
Not Available	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
Not Available	Completed	Treatment	Extrauterine Pregnancy / Infertilities	1
Not Available	Completed	Treatment	Fasciitis	1
Not Available	Completed	Treatment	Graft Versus Host Disease (GVHD) / Mucositis	1
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)	1
Not Available	Completed	Treatment	Inflammatory Bowel Diseases (IBD)	1
Not Available	Completed	Treatment	L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
Not Available	Completed	Treatment	Leukemia, Lymphocytic, Acute	1
Not Available	Completed	Treatment	Leukemias	2
Not Available	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific	1
Not Available	Completed	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma	1
Not Available	Completed	Treatment	Lymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)	1
Not Available	Completed	Treatment	Lymphoma, Lymphoblastic	1
Not Available	Completed	Treatment	Malignant Lymphomas	1
Not Available	Completed	Treatment	Rheumatoid Arthritis	3
Not Available	Completed	Treatment	Sarcomas	1
Not Available	Completed	Treatment	T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
Not Available	Completed	Treatment	Synovitis of osteoarthritis	1
Not Available	Recruiting	Not Available	Bullous Pemphigoid (BP)	1
Not Available	Recruiting	Not Available	Psoriasis	1
Not Available	Recruiting	Other	Severe Aplastic Anemia (SAA)	1
Not Available	Recruiting	Treatment	Acute Lymphoblastic Leukemia Ph Positive	1
Not Available	Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia	1
Not Available	Recruiting	Treatment	Cancers	1
Not Available	Recruiting	Treatment	Chronic Myeloid Leukemia (CML) / Leukaemia, Acute / Myelodysplastic Syndrome	1
Not Available	Recruiting	Treatment	Crohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)	1
Not Available	Recruiting	Treatment	Flu caused by Influenza / Methotrexate / Rheumatoid Arthritis	1
Not Available	Recruiting	Treatment	Psoriatic Arthritis	1
Not Available	Recruiting	Treatment	Recurrence (Disease Attribute)	1
Not Available	Terminated	Treatment	Bruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome	1
Not Available	Terminated	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas	1
Not Available	Terminated	Treatment	Diabetic Macular Edema (DME)	1
Not Available	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)	1
Not Available	Terminated	Treatment	Leukemias / Malignant Lymphomas	1
Not Available	Terminated	Treatment	Sarcoma, Osteogenic	1
Not Available	Terminated	Treatment	T-Cell Lymphomas	1
Not Available	Unknown Status	Not Available	Cancer, Breast	1
Not Available	Unknown Status	Not Available	Juvenile Idiopathic Arthritis (JIA)	1
Not Available	Unknown Status	Not Available	Scleritis / Uveitis	1
Not Available	Unknown Status	Prevention	Graft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)	1
Not Available	Unknown Status	Treatment	Behcet's Syndrome / Uveal Disease	1
Not Available	Unknown Status	Treatment	Chediak-Higashi Syndrome / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Lymphohistiocytosis, Hemophagocytic / Virus-Associated Hemophagocytic Syndrome / X-Linked Lymphoproliferative Syndrome	1
Not Available	Unknown Status	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Renal Cancers	1
Not Available	Unknown Status	Treatment	Extrauterine Pregnancy / Persistent Pregnancy of Unknown Location	1
Not Available	Unknown Status	Treatment	Leukemias	2
Not Available	Unknown Status	Treatment	Malignant Lymphomas	1
Not Available	Unknown Status	Treatment	Rheumatoid Arthritis	1
Not Available	Unknown Status	Treatment	Sarcoma, Osteogenic	1
Not Available	Withdrawn	Treatment	Leptomeningeal Metastases	1
Not Available	Withdrawn	Treatment	Malignant Lymphomas	1

Pharmacoeconomics

Manufacturers

Abic ltd
Pharmacia and upjohn co
Hospira inc
App pharmaceuticals llc
Abraxis pharmaceutical products
Bedford laboratories div ben venue laboratories inc
Norbrook laboratories ltd
Pharmachemie usa inc
Bioniche pharma usa llc
Ebewe pharma ges mbh nfg kg
Pharmachemie bv
Bristol laboratories inc div bristol myers co
Bristol myers co
Bristol myers squibb
Barr laboratories inc
Dava pharmaceuticals inc
Duramed pharmaceuticals inc sub barr laboratories inc
Mylan pharmaceuticals inc
Roxane laboratories inc

Packagers

Apotheca Inc.
APP Pharmaceuticals
A-S Medication Solutions LLC
Barr Pharmaceuticals
Baxter International Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Bigmar Bioren Pharmaceuticals Sa
Bryant Ranch Prepack
DAVA Pharmaceuticals
Dispensing Solutions
Diversified Healthcare Services Inc.
Duramed
Ebewe Pharma
Excella GmbH
Gallipot
Generamedix Inc.
Hospira Inc.
Intas Pharmaceuticals Ltd.
Lake Erie Medical and Surgical Supply
Major Pharmaceuticals
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Pharmedix
Physicians Total Care Inc.
Qualitest
Rebel Distributors Corp.
Remedy Repack
Roxane Labs
Spectrum Pharmaceuticals
UDL Laboratories
Wyeth Pharmaceuticals

Dosage forms

Form	Route	Strength
Injection	Intra-arterial; Intramuscular; Intrathecal; Intravenous	25 mg/mL
Injection, powder, lyophilized, for solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	1 g/1
Injection, solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	1 g/40mL
Injection, solution	Intra-arterial; Intramuscular; Intravenous	25 mg/mL
Tablet	Oral	2.5 mg/1
Liquid	Intravenous	10 mg
Liquid	Intravenous	2.5 mg
Liquid	Intravenous	25 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	25 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular	10 mg
Solution	Intra-arterial; Intramuscular; Intravenous	25 mg
Solution	Intravenous	25 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	10 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	15 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	20 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	7.5 mg
Injection, solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	25 mg/mL
Powder, for solution	Intramuscular; Intrathecal; Intravenous	20 mg
Liquid	Intramuscular; Intrathecal; Intravenous	25 mg
Liquid	Intramuscular; Intrathecal; Intravenous	50 mg
Liquid	Intra-arterial; Intramuscular; Intrathecal; Intravenous	25 mg
Solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular	25 mg
Tablet	Oral	10 mg
Powder, for solution	Intra-arterial; Intramuscular; Intrathecal; Intravenous	20 mg
Solution	Intra-arterial; Intramuscular; Intravenous	10 mg
Solution	Intra-arterial; Intramuscular; Intravenous	15 mg
Solution	Intra-arterial; Intramuscular; Intravenous	20 mg
Solution	Intra-arterial; Intramuscular; Intravenous	7.5 mg
Solution	Subcutaneous	10 mg
Solution	Subcutaneous	12.5 mg
Solution	Subcutaneous	15 mg
Solution	Subcutaneous	17.5 mg
Solution	Subcutaneous	20 mg
Solution	Subcutaneous	22.5 mg
Solution	Subcutaneous	25 mg
Solution	Subcutaneous	7.5 mg
Injection, solution	Subcutaneous	10 mg
Injection, solution	Subcutaneous	12.5 mg
Injection, solution	Subcutaneous	15 mg
Injection, solution	Subcutaneous	17.5 mg
Injection, solution	Subcutaneous	20 mg
Injection, solution	Subcutaneous	22.5 mg
Injection, solution	Subcutaneous	25 mg
Injection, solution	Subcutaneous	7.5 mg
Injection, solution	Subcutaneous	10 mg/.4mL
Injection, solution	Subcutaneous	12.5 mg/.4mL
Injection, solution	Subcutaneous	15 mg/.4mL
Injection, solution	Subcutaneous	17.5 mg/.4mL
Injection, solution	Subcutaneous	20 mg/.4mL
Injection, solution	Subcutaneous	22.5 mg/.4mL
Injection, solution	Subcutaneous	25 mg/.4mL
Injection, solution	Subcutaneous	7.5 mg/.4mL
Injection, solution	Subcutaneous	10 mg/.2mL
Injection, solution	Subcutaneous	12.5 mg/.25mL
Injection, solution	Subcutaneous	15 mg/.3mL
Injection, solution	Subcutaneous	17.5 mg/.35mL
Injection, solution	Subcutaneous	22.5 mg/.45mL
Injection, solution	Subcutaneous	25 mg/.5mL
Injection, solution	Subcutaneous	27.5 mg/.55mL
Injection, solution	Subcutaneous	30 mg/.6mL
Injection, solution	Subcutaneous	7.5 mg/.15mL
Tablet	Oral	2.5 mg
Tablet, film coated	Oral	10 mg/1
Tablet, film coated	Oral	15 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet, film coated	Oral	7.5 mg/1
Solution	Oral	2.5 mg/mL

Prices

Unit description	Cost	Unit
Methotrexate powder	261.33USD	g
Rheumatrex 8 2.5 mg tablet Disp Pack	169.98USD	disp
Rheumatrex 24 2.5 mg tablet Disp Pack	129.06USD	disp
Rheumatrex 20 2.5 mg tablet Disp Pack	107.59USD	disp
Rheumatrex 12 2.5 mg tablet Disp Pack	63.65USD	disp
Methotrexate Sodium 25 mg/ml (pf) Solution 40ml Vial	58.99USD	vial
Trexall 15 mg tablet	25.98USD	tablet
Methotrexate Sodium 25 mg/ml (pf) Solution 10ml Vial	24.99USD	vial
Trexall 10 mg tablet	17.67USD	tablet
Methotrexate Sodium 25 mg/ml Solution 1 Vial = 2ml	15.11USD	vial
Methotrexate Sodium 25 mg/ml (pf) Solution 2ml Vial	14.99USD	vial
Trexall 7.5 mg tablet	12.99USD	tablet
Rheumatrex 2.5 mg tablet	11.23USD	tablet
Trexall 5 mg tablet	8.66USD	tablet
Methotrexate Sod. (Preserved) 25 mg/ml	8.38USD	ml
Methotrexate Sod.(Unpreserved) 25 mg/ml	4.56USD	ml
Methotrexate 2.5 mg tablet	2.71USD	tablet
Methotrexate 10 mg Tablet	2.58USD	tablet
Ratio-Methotrexate Sodium 2.5 mg Tablet	0.66USD	tablet
Apo-Methotrexate 2.5 mg Tablet	0.66USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8480631	No	2010-03-19	2030-03-19
USRE44847	No	1999-08-10	2019-08-10
US8579865	No	2010-03-19	2030-03-19
US8945063	No	2010-03-19	2030-03-19
USRE44846	No	1999-08-10	2019-08-10
US8021335	No	2006-10-04	2026-10-04
US6746429	No	2000-04-12	2020-04-12
US8562564	No	2006-01-24	2026-01-24
US7744582	No	1999-08-10	2019-08-10
US7776015	No	1999-08-10	2019-08-10
US8664231	No	2009-06-01	2029-06-01
US9533102	No	2006-01-24	2026-01-24
US9629959	No	2006-01-24	2026-01-24
US9421333	No	2010-03-19	2030-03-19
US9259427	No	2013-01-02	2033-01-02

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	195 °C	Not Available
water solubility	2600 mg/L	Not Available
logP	-1.85	HANSCH,C ET AL. (1995)
Caco2 permeability	-5.92	ADME Research, USCD
pKa	4.7	SANGSTER (1994)

Predicted Properties

Property	Value	Source
Water Solubility	0.171 mg/mL	ALOGPS
logP	-0.91	ALOGPS
logP	-0.5	ChemAxon
logS	-3.4	ALOGPS
pKa (Strongest Acidic)	3.41	ChemAxon
pKa (Strongest Basic)	2.81	ChemAxon
Physiological Charge	-2	ChemAxon
Hydrogen Acceptor Count	12	ChemAxon
Hydrogen Donor Count	5	ChemAxon
Polar Surface Area	210.54 Å²	ChemAxon
Rotatable Bond Count	9	ChemAxon
Refractivity	119.21 m³·mol^-1	ChemAxon
Polarizability	44.54 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.8261
Blood Brain Barrier	-	0.9467
Caco-2 permeable	-	0.7754
P-glycoprotein substrate	Substrate	0.8172
P-glycoprotein inhibitor I	Non-inhibitor	0.7752
P-glycoprotein inhibitor II	Non-inhibitor	0.9879
Renal organic cation transporter	Non-inhibitor	0.8886
CYP450 2C9 substrate	Non-substrate	0.85
CYP450 2D6 substrate	Non-substrate	0.7968
CYP450 3A4 substrate	Substrate	0.5177
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8333
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9739
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.9517
Biodegradation	Not ready biodegradable	0.9741
Rat acute toxicity	3.4955 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9564
hERG inhibition (predictor II)	Non-inhibitor	0.6958

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (10.1 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Mass Spectrum (Electron Ionization)	MS	splash10-0fai-6900000000-25b0e287457fb3845ef4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-1819500000-3159955c0d961d305b13
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-0619400000-9a6d686008b68ac436ba
MS/MS Spectrum - , positive	LC-MS/MS	splash10-004i-2902000000-526ede2e4de609cb3d44
1H NMR Spectrum	1D NMR	Not Applicable
13C NMR Spectrum	1D NMR	Not Applicable

Taxonomy

Description: This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom: Organic compounds
Super Class: Organic acids and derivatives
Class: Carboxylic acids and derivatives
Sub Class: Amino acids, peptides, and analogues
Direct Parent: Glutamic acid and derivatives
Alternative Parents: N-acyl-alpha amino acids / Hippuric acids / Pteridines and derivatives / Aminobenzamides / Aniline and substituted anilines / Dialkylarylamines / Benzoyl derivatives / Aminopyrimidines and derivatives / Aralkylamines / Pyrazines
show 11 more
Substituents: Glutamic acid or derivatives / Hippuric acid or derivatives / Hippuric acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Aminobenzamide / Aminobenzoic acid or derivatives / Pteridine / Benzamide / Benzoic acid or derivatives
show 30 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: monocarboxylic acid amide, dicarboxylic acid, pteridines (CHEBI:44185)

Targets

Property	Measurement	pH	Temperature (°C)	References
EC 50 (nM)	12.5	7.4	30	16279780
EC 50 (nM)	13.3	7.4	30	17552508
IC 50 (nM)	0.6	N/A	N/A	8568827
IC 50 (nM)	0.7	N/A	N/A	7562910
IC 50 (nM)	0.82	N/A	N/A	8691451
IC 50 (nM)	1	N/A	N/A	18205293
IC 50 (nM)	1.2	N/A	N/A	6403710 / 8568827
IC 50 (nM)	1.7	N/A	N/A	4009615
IC 50 (nM)	11.2	N/A	N/A	8035423
IC 50 (nM)	13.8	N/A	N/A	11052789
IC 50 (nM)	14.5	N/A	N/A	11052789
IC 50 (nM)	2	N/A	N/A	11052790
IC 50 (nM)	2.7	N/A	N/A	1578484 / 3091832
IC 50 (nM)	20	N/A	N/A	2918496 / 17569517 / 18800768 / 22739090
IC 50 (nM)	20	7.4	30	18072727 / 19719239
IC 50 (nM)	22	N/A	N/A	10956221 / 11052789 / 11960504 / 12408727 / 12570380 / 15615538 / 16078850 / 18605720 / 20056546 / 20092323 / 21550809
IC 50 (nM)	22	7.4	30	16279780 / 17552508
IC 50 (nM)	24	N/A	N/A	1992122 / 1995880
IC 50 (nM)	24.3	7	30	15561838
IC 50 (nM)	25	N/A	N/A	1992118
IC 50 (nM)	26	N/A	N/A	7365749
IC 50 (nM)	3.3	N/A	N/A	6585550
IC 50 (nM)	3.8	N/A	N/A	3339615
IC 50 (nM)	3.9	N/A	N/A	1992121
IC 50 (nM)	30	N/A	N/A	2296020
IC 50 (nM)	32.94	N/A	N/A	18555562
IC 50 (nM)	35	N/A	N/A	17127067
IC 50 (nM)	38	N/A	N/A	8691474
IC 50 (nM)	4	N/A	N/A	8164259
IC 50 (nM)	4.3	N/A	N/A	2704031 / 2738891
IC 50 (nM)	40	N/A	N/A	7562910
IC 50 (nM)	44	N/A	N/A	11052789
IC 50 (nM)	6	N/A	N/A	11052789
IC 50 (nM)	66	N/A	N/A	11384244
IC 50 (nM)	7.9	N/A	N/A	6772788
IC 50 (nM)	720	N/A	N/A	8568828
IC 50 (nM)	80	N/A	N/A	20350811
IC 50 (nM)	9	N/A	N/A	15615522 / 17127067
IC 50 (nM)	9.6	N/A	N/A	6772788
Ki (nM)	0	N/A	N/A	7877140 / 22946585
Ki (nM)	0.00519	N/A	N/A	9857098
Ki (nM)	0.038	N/A	N/A	10360757
Ki (nM)	0.11	N/A	N/A	7877140
Ki (nM)	0.179	N/A	N/A	10360757
Ki (nM)	4420	N/A	N/A	17532099

Details1. Dihydrofolate reductase

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Nadph binding
Specific Function: Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA pre...
Gene Name: DHFR
Uniprot ID: P00374
Uniprot Name: Dihydrofolate reductase
Molecular Weight: 21452.61 Da

References

Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI: Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. Epub 2006 Sep 12. [PubMed:16971132]
Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007 Mar;26(1):153-81. [PubMed:17333344]
Bennett B, Langan P, Coates L, Mustyakimov M, Schoenborn B, Howell EE, Dealwis C: Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18493-8. Epub 2006 Nov 27. [PubMed:17130456]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Totani K, Matsuo I, Ihara Y, Ito Y: High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates. Bioorg Med Chem. 2006 Aug 1;14(15):5220-9. Epub 2006 May 2. [PubMed:16647263]
Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Handa H: A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol. 2006 Nov;70(5):1832-9. Epub 2006 Aug 25. [PubMed:16936229]

Enzymes

Details1. Dihydrofolate reductase

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Nadph binding
Specific Function: Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA pre...
Gene Name: DHFR
Uniprot ID: P00374
Uniprot Name: Dihydrofolate reductase
Molecular Weight: 21452.61 Da

References

Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865]

Details2. Aldehyde oxidase

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Xanthine dehydrogenase activity
Specific Function: Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name: AOX1
Uniprot ID: Q06278
Uniprot Name: Aldehyde oxidase
Molecular Weight: 147916.735 Da

References

Zientek M, Jiang Y, Youdim K, Obach RS: In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 2010 Aug;38(8):1322-7. doi: 10.1124/dmd.110.033555. Epub 2010 May 5. [PubMed:20444863]
Baggott JE, Morgan SL: Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum. 2009 Aug;60(8):2257-61. doi: 10.1002/art.24685. [PubMed:19644884]
Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C: Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol. 1999 Apr;51(4):411-8. [PubMed:10385213]

Details3. Methylenetetrahydrofolate reductase

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Protein complex binding
Specific Function: Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name: MTHFR
Uniprot ID: P42898
Uniprot Name: Methylenetetrahydrofolate reductase
Molecular Weight: 74595.895 Da

References

Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865]
Kremer JM: Methotrexate pharmacogenomics. Ann Rheum Dis. 2006 Sep;65(9):1121-3. [PubMed:16905578]

Details4. 6-phosphogluconate dehydrogenase, decarboxylating

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function: Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name: PGD
Uniprot ID: P52209
Uniprot Name: 6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight: 53139.56 Da

References

Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	3200	N/A	N/A	8863812

Details5. Folylpolyglutamate synthase, mitochondrial

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Tetrahydrofolylpolyglutamate synthase activity
Specific Function: Catalyzes conversion of folates to polyglutamate derivatives allowing concentration of folate compounds in the cell and the intracellular retention of these cofactors, which are important substrate...
Gene Name: FPGS
Uniprot ID: Q05932
Uniprot Name: Folylpolyglutamate synthase, mitochondrial
Molecular Weight: 64608.53 Da

References

Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	>18000	N/A	N/A	21550809
IC 50 (nM)	100000	N/A	N/A	3091834
IC 50 (nM)	120000	N/A	N/A	3091832
IC 50 (nM)	170000	N/A	N/A	3091832 / 7562910 / 8164259
IC 50 (nM)	190000	N/A	N/A	4009615
IC 50 (nM)	29000	N/A	N/A	18605720 / 20056546
IC 50 (nM)	29000	7.4	30	16279780
IC 50 (nM)	3600	N/A	N/A	11384244
IC 50 (nM)	40000	N/A	N/A	6772788
IC 50 (nM)	600000	N/A	N/A	3100797
IC 50 (nM)	75000	N/A	N/A	7108907
IC 50 (nM)	86000	N/A	N/A	3121855
Ki (nM)	600	N/A	N/A	22946585

Details6. Thymidylate synthase

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Thymidylate synthase activity
Specific Function: Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name: TYMS
Uniprot ID: P04818
Uniprot Name: Thymidylate synthase
Molecular Weight: 35715.65 Da

References

Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	>20000	N/A	N/A	3121855

Details7. Bifunctional purine biosynthesis protein PURH

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Protein homodimerization activity
Specific Function: Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).
Gene Name: ATIC
Uniprot ID: P31939
Uniprot Name: Bifunctional purine biosynthesis protein PURH
Molecular Weight: 64615.255 Da

References

Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865]

Details8. Gamma-glutamyl hydrolase

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Omega peptidase activity
Specific Function: Hydrolyzes the polyglutamate sidechains of pteroylpolyglutamates. Progressively removes gamma-glutamyl residues from pteroylpoly-gamma-glutamate to yield pteroyl-alpha-glutamate (folic acid) and fr...
Gene Name: GGH
Uniprot ID: Q92820
Uniprot Name: Gamma-glutamyl hydrolase
Molecular Weight: 35964.045 Da

References

Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865]

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: No

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

Warnecke A, Fichtner I, Sass G, Kratz F: Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm (Weinheim). 2007 Aug;340(8):389-95. [PubMed:17628030]
Xie WJ, Feng YP, Cao SL, Zhao YF: [Study of the interaction between methotrexate and bovine serum albumin by spectrometry]. Guang Pu Xue Yu Guang Pu Fen Xi. 2006 Oct;26(10):1876-9. [PubMed:17205742]

Transporters

Details1. Canalicular multispecific organic anion transporter 2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Organic anion transmembrane transporter activity
Specific Function: May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name: ABCC3
Uniprot ID: O15438
Uniprot Name: Canalicular multispecific organic anion transporter 2
Molecular Weight: 169341.14 Da

References

Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002 Jan;19(1):34-41. [PubMed:11837698]
Oleschuk CJ, Deeley RG, Cole SP: Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G280-9. Epub 2002 Oct 9. [PubMed:12388190]
Hirohashi T, Suzuki H, Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999 May 21;274(21):15181-5. [PubMed:10329726]
Zeng H, Liu G, Rea PA, Kruh GD: Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000 Sep 1;60(17):4779-84. [PubMed:10987286]
Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. [PubMed:12731885]
Li T, Ito K, Horie T: Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10. [PubMed:12909565]
Zehnpfennig B, Urbatsch IL, Galla HJ: Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30. doi: 10.1021/bi9001908. [PubMed:19334674]

Details2. Multidrug resistance-associated protein 4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Atpase activity, coupled to transmembrane movement of substances
Specific Function: May be an organic anion pump relevant to cellular detoxification.
Gene Name: ABCC4
Uniprot ID: O15439
Uniprot Name: Multidrug resistance-associated protein 4
Molecular Weight: 149525.33 Da

References

Chen ZS, Lee K, Kruh GD: Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001 Sep 7;276(36):33747-54. Epub 2001 Jul 10. [PubMed:11447229]
Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481]
Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890]
van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. [PubMed:11856762]

Details3. Multidrug resistance-associated protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Transporter activity
Specific Function: Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name: ABCC1
Uniprot ID: P33527
Uniprot Name: Multidrug resistance-associated protein 1
Molecular Weight: 171589.5 Da

References

Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796]
Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. [PubMed:12731885]

Details4. Solute carrier family 22 member 6

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name: SLC22A6
Uniprot ID: Q4U2R8
Uniprot Name: Solute carrier family 22 member 6
Molecular Weight: 61815.78 Da

References

Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570]
Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014]
Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. [PubMed:20460822]

Details5. Multidrug resistance-associated protein 7

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Atpase activity, coupled to transmembrane movement of substances
Specific Function: ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name: ABCC10
Uniprot ID: Q5T3U5
Uniprot Name: Multidrug resistance-associated protein 7
Molecular Weight: 161627.375 Da

References

Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]

Details6. Solute carrier family 22 member 8

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name: SLC22A8
Uniprot ID: Q8TCC7
Uniprot Name: Solute carrier family 22 member 8
Molecular Weight: 59855.585 Da

References

Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. [PubMed:20460822]

Details7. Canalicular multispecific organic anion transporter 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Organic anion transmembrane transporter activity
Specific Function: Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name: ABCC2
Uniprot ID: Q92887
Uniprot Name: Canalicular multispecific organic anion transporter 1
Molecular Weight: 174205.64 Da

References

Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y: Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Pharm Res. 2001 May;18(5):579-86. [PubMed:11465411]
Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y: Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 1997 Aug 15;57(16):3506-10. [PubMed:9270020]
Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5. [PubMed:10363967]
Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523]
Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, Liu X: Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res. 2003 Jan;20(1):31-7. [PubMed:12608533]

Details8. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, Kwan E, Stewart BW, Mechetner EB, Gudkov AV, Roninson IB: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer. 1996 Mar 1;65(5):613-9. [PubMed:8598312]

Details9. Solute carrier organic anion transporter family member 1A2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name: SLCO1A2
Uniprot ID: P46721
Uniprot Name: Solute carrier organic anion transporter family member 1A2
Molecular Weight: 74144.105 Da

References

Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B: Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95. [PubMed:11713643]

Details10. Monocarboxylate transporter 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Symporter activity
Specific Function: Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name: SLC16A1
Uniprot ID: P53985
Uniprot Name: Monocarboxylate transporter 1
Molecular Weight: 53943.685 Da

References

Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682]

Details11. ATP-binding cassette sub-family C member 11

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Purine nucleotide transmembrane transporter activity
Specific Function: Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a ...
Gene Name: ABCC11
Uniprot ID: Q96J66
Uniprot Name: ATP-binding cassette sub-family C member 11
Molecular Weight: 154299.625 Da

References

Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867]

Details12. Solute carrier organic anion transporter family member 1B3

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name: SLCO1B3
Uniprot ID: Q9NPD5
Uniprot Name: Solute carrier organic anion transporter family member 1B3
Molecular Weight: 77402.175 Da

References

Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. [PubMed:11375950]

Details13. Solute carrier family 22 member 11

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name: SLC22A11
Uniprot ID: Q9NSA0
Uniprot Name: Solute carrier family 22 member 11
Molecular Weight: 59970.945 Da

References

Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]

Details14. Solute carrier organic anion transporter family member 1C1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Thyroid hormone transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
Gene Name: SLCO1C1
Uniprot ID: Q9NYB5
Uniprot Name: Solute carrier organic anion transporter family member 1C1
Molecular Weight: 78695.625 Da

References

Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693]

Details15. Solute carrier organic anion transporter family member 3A1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 an...
Gene Name: SLCO3A1
Uniprot ID: Q9UIG8
Uniprot Name: Solute carrier organic anion transporter family member 3A1
Molecular Weight: 76552.135 Da

References

Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946]

Details16. ATP-binding cassette sub-family G member 2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name: ABCG2
Uniprot ID: Q9UNQ0
Uniprot Name: ATP-binding cassette sub-family G member 2
Molecular Weight: 72313.47 Da

References

Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923]
Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J. 2003 Aug 1;373(Pt 3):767-74. [PubMed:12741957]
Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. [PubMed:12874005]
Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43. [PubMed:14500392]
Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159]
Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, Chang XB: Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. Biochemistry. 2009 Sep 29;48(38):9122-31. doi: 10.1021/bi900675v. [PubMed:19691360]
Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995]
Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18. [PubMed:19232821]

Details17. Solute carrier family 22 member 7

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name: SLC22A7
Uniprot ID: Q9Y694
Uniprot Name: Solute carrier family 22 member 7
Molecular Weight: 60025.025 Da

References

Sun W, Wu RR, van Poelje PD, Erion MD: Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 2001 May 4;283(2):417-22. [PubMed:11327718]
Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]

Details18. Solute carrier organic anion transporter family member 1B1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name: SLCO1B1
Uniprot ID: Q9Y6L6
Uniprot Name: Solute carrier organic anion transporter family member 1B1
Molecular Weight: 76447.99 Da

References

Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. [PubMed:11375950]
van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH: Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos. 2009 Feb;37(2):277-81. doi: 10.1124/dmd.108.024315. Epub 2008 Nov 20. [PubMed:19022939]

Details19. Proton-coupled folate transporter

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Methotrexate transporter activity
Specific Function: Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithel...
Gene Name: SLC46A1
Uniprot ID: Q96NT5
Uniprot Name: Proton-coupled folate transporter
Molecular Weight: 49770.04 Da

References

Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. [PubMed:17475902]

Details20. Solute carrier organic anion transporter family member 4C1

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ...
Gene Name: SLCO4C1
Uniprot ID: Q6ZQN7
Uniprot Name: Solute carrier organic anion transporter family member 4C1
Molecular Weight: 78947.525 Da

References

Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	3500	N/A	N/A	10821704

Details21. Folate transporter 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Reduced folate carrier activity
Specific Function: Transporter for the intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely th...
Gene Name: SLC19A1
Uniprot ID: P41440
Uniprot Name: Folate transporter 1
Molecular Weight: 64867.62 Da

References

Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID: Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006 Dec 1;127(5):917-28. [PubMed:17129779]

Details22. Folate receptor alpha

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Receptor activity
Specific Function: Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analo...
Gene Name: FOLR1
Uniprot ID: P15328
Uniprot Name: Folate receptor alpha
Molecular Weight: 29818.94 Da

References

Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, Grover R, Arya V, Dhir V, Gupta R, Kumar U, Juyal RC, B K T: Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics. 2008 Dec;18(12):1041-9. [PubMed:19093297]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:23

Methotrexate

Identification

Structure for DB00563 (Methotrexate)

Pharmacology

Reactions:

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References

References

References

References

References

References

References

References

Carriers

References

Transporters

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References